Mifepristone (RU-486) treatment for depression and psychosis: a review of the therapeutic implications

<!DOCTYPE html> <html lang="en" > <head > <meta charset="UTF-8" /> <meta http-equiv="X-UA-Compatible" content="IE=edge" /> <meta name="HandheldFriendly" content="True" /> <meta name="MobileOptimized" content="320" /> <meta name="viewport" content="width=device-width, initial-scale=1.0" /> <link rel="stylesheet" href="/static/assets/style-b3a36f11.css" /> <script type="module" crossorigin="" src="/static/assets/base_style-d4f8bd56.js"></script> <link rel="stylesheet" href="/static/assets/style-ef962842.css" /> <link rel="stylesheet" href="/static/assets/style-3ade8b5c.css" /> <script type="module" crossorigin="" src="/static/assets/article_style-d757a0dd.js"></script> <style> @media screen and (min-width: 64em) { div.pmc-wm { background: repeat-y; background-image: url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='20' height='350' xmlns:xlink='http://www.w3.org/1999/xlink'%3E%3Cdefs%3E%3Cfilter x='-.02' y='0' width='1.05' height='1' id='c'%3E%3CfeFlood flood-color='%23FFF'/%3E%3CfeComposite in='SourceGraphic'/%3E%3C/filter%3E%3Ctext id='b' font-family='Helvetica' font-size='11pt' style='opacity:1;fill:%23005ea2;stroke:none;text-anchor:middle' x='175' y='14'%3E%3C/text%3E%3Cpath id='a' style='fill:%23005ea2' d='M0 8h350v3H0z'/%3E%3C/defs%3E%3Cuse xlink:href='%23a' transform='rotate(90 10 10)'/%3E%3Cuse xlink:href='%23b' transform='rotate(90 10 10)' filter='url(%23c)'/%3E%3C/svg%3E"); padding-left: 3rem; } } </style> <link rel="apple-touch-icon" sizes="180x180" href="/static/img/favicons/apple-touch-icon.png" /> <link rel="icon" type="image/png" sizes="48x48" href="/static/img/favicons/favicon-48x48.png" /> <link rel="icon" type="image/png" sizes="32x32" href="/static/img/favicons/favicon-32x32.png" /> <link rel="icon" type="image/png" sizes="16x16" href="/static/img/favicons/favicon-16x16.png" /> <link rel="manifest" href="/static/img/favicons/site.webmanifest" /> <link rel="mask-icon" href="/static/img/favicons/safari-pinned-tab.svg" color="#0071bc" /> <meta name="msapplication-config" content="/static/img/favicons/browserconfig.xml" /> <meta name="theme-color" content="#ffffff" /> <title> Mifepristone (RU-486) treatment for depression and psychosis: a review of the therapeutic implications - PMC </title>  <meta name="ncbi_app" content="cloudpmc-viewer" /> <meta name="ncbi_db" content="pmc" /> <meta name="ncbi_phid" content="1ECEC5737E74F83306C573002DD9E31A.m_1" />  <meta name="ncbi_pdid" content="article" /> <link rel="preconnect" href="https://www.google-analytics.com" /> <link rel="preconnect" href="https://cdn.ncbi.nlm.nih.gov" />  <script src="/static/assets/uswds-init.js"></script> <meta name="ncbi_domain" content="neurodist"> <meta name="ncbi_type" content="fulltext"> <meta name="ncbi_pcid" content="journal"> <link rel="canonical" href="https://pmc.ncbi.nlm.nih.gov/articles/PMC2671735/"> <meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE"> <meta name="citation_journal_title" content="Neuropsychiatric Disease and Treatment"> <meta name="citation_title" content="Mifepristone (RU-486) treatment for depression and psychosis: a review of the therapeutic implications"> <meta name="citation_author" content="Peter Gallagher"> <meta name="citation_author_institution" content="Stanley Research Centre, School of Neurology, Neurobiology and Psychiatry; University of Newcastle upon Tyne, UK"> <meta name="citation_author" content="Allan H Young"> <meta name="citation_author_institution" content="Stanley Research Centre, School of Neurology, Neurobiology and Psychiatry; University of Newcastle upon Tyne, UK"> <meta name="citation_publication_date" content="2006 Mar"> <meta name="citation_volume" content="2"> <meta name="citation_issue" content="1"> <meta name="citation_firstpage" content="33"> <meta name="citation_pmid" content="19412444"> <meta name="citation_abstract_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC2671735/"> <meta name="citation_fulltext_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC2671735/"> <meta name="citation_pdf_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC2671735/pdf/ndt-2-33.pdf"> <meta name="description" content="The mechanisms underlying the pathophysiology of severe psychiatric illnesses are complex, involving multiple neuronal and neurochemical pathways. A growing body of evidence indicates that alterations in hypothalamic–pituitary–adrenal (HPA) axis ..."> <meta name="og:title" content="Mifepristone (RU-486) treatment for depression and psychosis: a review of the therapeutic implications"> <meta name="og:type" content="article"> <meta name="og:site_name" content="PubMed Central (PMC)"> <meta name="og:description" content="The mechanisms underlying the pathophysiology of severe psychiatric illnesses are complex, involving multiple neuronal and neurochemical pathways. A growing body of evidence indicates that alterations in hypothalamic–pituitary–adrenal (HPA) axis ..."> <meta name="og:url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC2671735/"> <meta name="og:image" content="https://cdn.ncbi.nlm.nih.gov/pmc/cms/images/pmc-card-share.jpg?_=0"> <meta name="twitter:card" content="summary_large_image"> <meta name="twitter:site" content="@ncbi"> </head> <body > <a class="usa-skipnav " href="#main-content"> Skip to main content </a> <section class="usa-banner " aria-label="Official website of the United States government" > <div class="usa-accordion"> <header class="usa-banner__header"> <div class="usa-banner__inner"> <div class="grid-col-auto"> <img aria-hidden="true" class="usa-banner__header-flag" src="/static/img/us_flag.svg" alt="" /> </div> <div class="grid-col-fill tablet:grid-col-auto" aria-hidden="true"> <p class="usa-banner__header-text"> An official website of the United States government </p> <span class="usa-banner__header-action">Here's how you know</span> </div> <button type="button" class="usa-accordion__button usa-banner__button " aria-expanded="false" aria-controls="gov-banner-default" data-testid="storybook-django-banner" > <span class="usa-banner__button-text">Here's how you know</span> </button> </div> </header> <div class="usa-banner__content usa-accordion__content" id="gov-banner-default" hidden> <div class="grid-row grid-gap-lg"> <div class="usa-banner__guidance tablet:grid-col-6"> <img class="usa-banner__icon usa-media-block__img" src="/static/img/icon-dot-gov.svg" alt="" aria-hidden="true" /> <div class="usa-media-block__body"> <p> <strong>Official websites use .gov</strong> <br /> A <strong>.gov</strong> website belongs to an official government organization in the United States. </p> </div> </div> <div class="usa-banner__guidance tablet:grid-col-6"> <img class="usa-banner__icon usa-media-block__img" src="/static/img/icon-https.svg" alt="" aria-hidden="true" /> <div class="usa-media-block__body"> <p> <strong>Secure .gov websites use HTTPS</strong> <br /> A <strong>lock</strong> ( <span class="icon-lock"> <svg xmlns="http://www.w3.org/2000/svg" width="52" height="64" viewBox="0 0 52 64" class="usa-banner__lock-image" role="graphics-symbol" aria-labelledby="banner-lock-description" focusable="false"> <title id="banner-lock-title">Lock</title> <desc id="banner-lock-description"> Locked padlock icon </desc> <path fill="#000000" fill-rule="evenodd" d="M26 0c10.493 0 19 8.507 19 19v9h3a4 4 0 0 1 4 4v28a4 4 0 0 1-4 4H4a4 4 0 0 1-4-4V32a4 4 0 0 1 4-4h3v-9C7 8.507 15.507 0 26 0zm0 8c-5.979 0-10.843 4.77-10.996 10.712L15 19v9h22v-9c0-6.075-4.925-11-11-11z" /> </svg> </span>) or <strong>https://</strong> means you've safely connected to the .gov website. Share sensitive information only on official, secure websites. </p> </div> </div> </div> </div> </div> </section> <div class="usa-overlay"> </div> <header class="usa-header usa-header--extended usa-header--wide" data-testid="header" data-header > <div class="ncbi-header"> <div class="ncbi-header__container"> <a class="ncbi-header__logo-container" href="https://www.ncbi.nlm.nih.gov/"> <img alt=" NCBI home page " class="ncbi-header__logo-image" src="/static/img/ncbi-logos/nih-nlm-ncbi--white.svg" /> </a>  <button type="button" class="usa-menu-btn ncbi-header__hamburger-button " aria-label="Show menu" data-testid="navMenuButton" > <svg aria-hidden="true" class="ncbi-hamburger-icon" fill="none" focusable="false" height="21" viewBox="0 0 31 21" width="31" xmlns="http://www.w3.org/2000/svg"> <path clip-rule="evenodd" d="M0.125 20.75H30.875V17.3333H0.125V20.75ZM0.125 12.2083H30.875V8.79167H0.125V12.2083ZM0.125 0.25V3.66667H30.875V0.25H0.125Z" fill="#F1F1F1" fill-rule="evenodd" /> </svg> </button>  <div class="ncbi-header__desktop-buttons">  <button type="button" class="usa-button usa-button--unstyled ncbi-header__desktop-button " aria-expanded="false" aria-controls="search-field-desktop-navigation" aria-label="Show search overlay" data-testid="toggleSearchPanelButton" data-toggle-search-panel-button > <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" > <use xlink:href="/static/img/sprite.svg#search" /> </svg> Search </button>  <div class="ncbi-header__login-dropdown"> <button type="button" class="usa-button usa-button--unstyled ncbi-header__desktop-button ncbi-header__login-dropdown-button " aria-expanded="false" aria-controls="login-dropdown-menu" aria-label="Show login menu" data-testid="toggleLoginMenuDropdown" data-desktop-login-button > <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" > <use xlink:href="/static/img/sprite.svg#person" /> </svg> <span data-login-dropdown-text>Log in</span>  <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-less ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-up-arrow> <use xlink:href="/static/img/sprite.svg#expand_less" /> </svg>  <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-more ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-down-arrow> <use xlink:href="/static/img/sprite.svg#expand_more" /> </svg> </button>  <ul class="usa-nav__submenu ncbi-header__login-dropdown-menu" id="login-dropdown-menu" data-desktop-login-menu-dropdown hidden> <li class="usa-nav__submenu-item">  <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link " > Dashboard </a> </li> <li class="usa-nav__submenu-item">  <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link " > Publications </a> </li> <li class="usa-nav__submenu-item">  <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link " > Account settings </a> </li> <li class="usa-nav__submenu-item"> <button type="button" class="usa-button usa-button--outline ncbi-header__login-dropdown-logout-button " data-testid="desktopLogoutButton" data-desktop-logout-button > Log out </button> </li> </ul> </div> </div> </div> </div>  <div class="ncbi-search-panel ncbi--show-only-at-desktop" data-testid="searchPanel" data-header-search-panel hidden> <div class="ncbi-search-panel__container"> <form action="https://www.ncbi.nlm.nih.gov/search/all/" aria-describedby="search-field-desktop-navigation-help-text" autocomplete="off" class="usa-search usa-search--big ncbi-search-panel__form" data-testid="form" method="GET" role="search"> <label class="usa-sr-only" data-testid="label" for="search-field-desktop-navigation"> Search… </label> <input class="usa-input" data-testid="textInput" id="search-field-desktop-navigation" name="term" placeholder="Search NCBI" type="search" value="" /> <button type="submit" class="usa-button " data-testid="button" > <span class="usa-search__submit-text"> Search NCBI </span> </button> </form> </div> </div> <nav aria-label="Primary navigation" class="usa-nav"> <p class="usa-sr-only" id="primary-navigation-sr-only-title"> Primary site navigation </p>  <button type="button" class="usa-nav__close ncbi-nav__close-button " aria-label="Close navigation menu" data-testid="navCloseButton" > <img src="/static/img/usa-icons/close.svg" alt="Close" /> </button>  <form class="usa-search usa-search--small ncbi--hide-at-desktop margin-top-6" role="search"> <label class="usa-sr-only" for="search-field"> Search </label> <input class="usa-input" id="search-field-mobile-navigation" type="search" placeholder="Search NCBI" name="search" /> <button type="submit" class="usa-button " >  <img src="data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIGhlaWdodD0iMjQiIHZpZXdCb3g9IjAgMCAyNCAyNCIgd2lkdGg9IjI0Ij48cGF0aCBkPSJNMCAwaDI0djI0SDB6IiBmaWxsPSJub25lIi8+PHBhdGggZmlsbD0iI2ZmZiIgZD0iTTE1LjUgMTRoLS43OWwtLjI4LS4yN0E2LjQ3MSA2LjQ3MSAwIDAgMCAxNiA5LjUgNi41IDYuNSAwIDEgMCA5LjUgMTZjMS42MSAwIDMuMDktLjU5IDQuMjMtMS41N2wuMjcuMjh2Ljc5bDUgNC45OUwyMC40OSAxOWwtNC45OS01em0tNiAwQzcuMDEgMTQgNSAxMS45OSA1IDkuNVM3LjAxIDUgOS41IDUgMTQgNy4wMSAxNCA5LjUgMTEuOTkgMTQgOS41IDE0eiIvPjwvc3ZnPg==" class="usa-search__submit-icon" alt="Search" /> </button> </form>   <div class="ncbi-nav__mobile-login-menu ncbi--hide-at-desktop" data-mobile-login-menu hidden> <p class="ncbi-nav__mobile-login-menu-status"> Logged in as: <strong class="ncbi-nav__mobile-login-menu-email" data-mobile-login-email-text></strong> </p> <ul class="usa-nav__primary usa-accordion"> <li class="usa-nav__primary-item"> <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link " > Dashboard </a> </li> <li class="usa-nav__primary-item"> <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link " > Publications </a> </li> <li class="usa-nav__primary-item"> <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link " > Account settings </a> </li> </ul> </div> <button type="button" class="usa-button ncbi-nav__mobile-login-button ncbi--hide-at-desktop " data-testid="mobileLoginButton" data-mobile-login-button > Log in </button> </nav> </header> <section class="pmc-header pmc-header--basic" aria-label="PMC Header with search box"> <div class="pmc-nav-container"> <div class="pmc-header__bar"> <div class="pmc-header__logo"> <a href="/" title="Home" aria-label="PMC Home"></a> </div> <button type="button" class="usa-button usa-button--unstyled pmc-header__search__button" aria-label="Open search" data-ga-category="search" data-ga-action="PMC" data-ga-label="pmc_search_panel_mobile" > <svg class="usa-icon width-4 height-4 pmc-icon__open" aria-hidden="true" focusable="false" role="img"> <use xlink:href="/static/img/sprite.svg#search"></use> </svg> <svg class="usa-icon width-4 height-4 pmc-icon__close" aria-hidden="true" focusable="false" role="img"> <use xlink:href="/static/img/sprite.svg#close"></use> </svg> </button> </div> <div class="pmc-header__search"> <form class="usa-search usa-search--extra usa-search--article-right-column pmc-header__search__form" autocomplete="off" role="search"> <label class="usa-sr-only" for="pmc-search">Search PMC Full-Text Archive</label> <span class="autoComplete_wrapper flex-1"> <input class="usa-input width-full maxw-none" required="required" placeholder="Search PMC Full-Text Archive" id="pmc-search" type="search" name="term" data-autocomplete-url="https://pmc.ncbi.nlm.nih.gov/autocomp/search/autocomp/"/> </span> <button class="usa-button" type="submit" formaction="https://www.ncbi.nlm.nih.gov/pmc/" data-ga-category="search" data-ga-action="PMC" data-ga-label="PMC_search_button" > <span class="usa-search__submit-text">Search in PMC</span> <img src="/static/img/usa-icons-bg/search--white.svg" class="usa-search__submit-icon" alt="Search" /> </button> </form> <ul class="pmc-header__search__menu"> <li> <a class="usa-link" href="https://www.ncbi.nlm.nih.gov/pmc/advanced/" data-ga-action="featured_link" data-ga-label="advanced_search"> Advanced Search </a> </li> <li> <a class="usa-link" href="/journals/" data-ga-action="featured_link" data-ga-label="journal list"> Journal List </a> </li> <li> <a class="usa-link" href="/about/userguide/" data-ga-action="featured_link" data-ga-label="user guide"> User Guide </a> </li> </ul> </div> </div> </section> <div class="usa-section padding-top-0 desktop:padding-top-6 pmc-article-section" data-article-db="pmc" data-article-id="2671735"> <div class="grid-container pmc-actions-bar" aria-label="Actions bar" role="complementary"> <div class="grid-row"> <div class="grid-col-fill display-flex"> <div class="display-flex"> <ul class="usa-list usa-list--unstyled usa-list--horizontal"> <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob"> <button type="button" class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex" aria-label="Open resources" data-extra-class="is-visible-resources" data-ga-category="resources_accordion" data-ga-action="click" data-ga-label="mobile_icon" > <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img"> <use xlink:href="/static/img/sprite.svg#more_vert"></use> </svg> </button> </li> <li class="margin-right-2 mobile-lg:margin-right-4 display-flex"> <a href="pdf/ndt-2-33.pdf" class="usa-link display-flex usa-tooltip" role="button" title="Download PDF" data-position="bottom" aria-label="Download PDF" data-ga-category="actions" data-ga-action="click" data-ga-label="pdf_download_mobile" > <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img"> <use xlink:href="/static/img/sprite.svg#file_download"></use> </svg> </a> </li> <li class="margin-right-2 mobile-lg:margin-right-4 display-flex"> <button class="usa-button usa-button--unstyled usa-tooltip collections-dialog-trigger collections-button display-flex collections-button-empty" title="Add to Collections" data-position="bottom" aria-label="Save article in MyNCBI collections." data-ga-category="actions" data-ga-action="click" data-ga-label="collections_button_mobile" data-collections-open-dialog-enabled="false" data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC2671735%2F%23open-collections-dialog" data-in-collections="false" > <svg class="usa-icon width-4 height-4 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden> <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use> </svg> <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden> <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use> </svg> </button> </li> <li class="margin-right-2 mobile-lg:margin-right-4 display-flex"> <button role="button" class="usa-button usa-button--unstyled usa-tooltip citation-dialog-trigger display-flex" aria-label="Open dialog with citation text in different styles" title="Cite" data-position="bottom" data-ga-category="actions" data-ga-action="open" data-ga-label="cite_mobile" data-all-citations-url="/resources/citations/2671735/" data-citation-style="nlm" data-download-format-link="/resources/citations/2671735/export/" > <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden> <use xlink:href="/static/img/sprite.svg#format_quote"></use> </svg> </button> </li> <li class="pmc-permalink display-flex"> <button type="button" class="usa-button usa-button--unstyled usa-tooltip display-flex" title="Permalink" data-position="bottom" aria-label="Show article permalink" aria-expanded="false" aria-haspopup="true" data-ga-category="actions" data-ga-action="open" data-ga-label="permalink_mobile" > <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img"> <use xlink:href="/static/img/sprite.svg#share"></use> </svg> </button> <div class="pmc-permalink__dropdown" hidden> <div class="pmc-permalink__dropdown__container"> <h2 class="usa-modal__heading margin-top-0 margin-bottom-2">PERMALINK</h2> <div class="pmc-permalink__dropdown__content"> <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC2671735/" aria-label="Article permalink"> <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link"> <svg class="usa-icon" aria-hidden="true" focusable="false" role="img"> <use xlink:href="/static/img/sprite.svg#content_copy"></use> </svg> <span class="margin-left-1">Copy</span> </button> </div> </div> </div> </li> </ul> </div> <button type="button" class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex" aria-label="Open article navigation" data-extra-class="is-visible-in-page" data-ga-category="actions" data-ga-action="open" data-ga-label="article_nav_mobile" > <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img"> <use xlink:href="/static/img/sprite.svg#list"></use> </svg> </button> </div> </div> </div> <div class="grid-container desktop:padding-left-6"> <div id="article-container" class="grid-row grid-gap"> <div class="grid-col-12 desktop:grid-col-8 order-2 pmc-layout__content"> <div class="grid-container padding-left-0 padding-right-0"> <div class="grid-row desktop:margin-left-neg-6"> <div class="grid-col-12"> <div class="pmc-layout__disclaimer" role="complementary" aria-label="Disclaimer note"> As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with, the contents by NLM or the National Institutes of Health.<br/> Learn more: <a class="usa-link" data-ga-category="Link click" data-ga-action="Disclaimer" data-ga-label="New disclaimer box" href="/about/disclaimer/">PMC Disclaimer</a> | <a class="usa-link" data-ga-category="Link click" data-ga-action="PMC Copyright Notice" data-ga-label="New disclaimer box" href="/about/copyright/"> PMC Copyright Notice </a> </div> </div> </div> <div class="grid-row pmc-wm desktop:margin-left-neg-6">  <main id="main-content" class="usa-layout-docs__main usa-layout-docs grid-col-12 pmc-layout pmc-prose padding-0" > <section class="pmc-journal-banner text-center line-height-none" aria-label="Journal banner"><img src="https://cdn.ncbi.nlm.nih.gov/pmc/banners/logo-neurodist.gif" alt="Neuropsychiatric Disease and Treatment logo" usemap="#pmc-banner-imagemap" width="500" height="75"><map name="pmc-banner-imagemap"><area alt="Link to Neuropsychiatric Disease and Treatment" title="Link to Neuropsychiatric Disease and Treatment" shape="default" href="http://www.dovepress.com/neuropsychiatric-disease-and-treatment-journal" target="_blank" rel="noopener noreferrer"></map></section><article lang="en"><section aria-label="Article citation and metadata"><section class="pmc-layout__citation font-secondary font-xs"><div> <div class="display-inline-block"><button type="button" class="cursor-pointer text-no-underline bg-transparent border-0 padding-0 text-left margin-0 text-normal text-primary" aria-controls="journal_context_menu">Neuropsychiatr Dis Treat</button></div>. 2006 Mar;2(1):33–42.</div> <nav id="journal_context_menu" hidden="hidden"><ul class="menu-list font-family-ui" role="menu"> <li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/pmc/?term=%22Neuropsychiatr%20Dis%20Treat%22%5Bjour%5D" class="usa-link" role="menuitem">Search in PMC</a></li> <li role="presentation"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Neuropsychiatr%20Dis%20Treat%22%5Bjour%5D" lang="en" class="usa-link" role="menuitem">Search in PubMed</a></li> <li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Neuropsychiatr%20Dis%20Treat%22%5BTitle%20Abbreviation%5D" class="usa-link" role="menuitem">View in NLM Catalog</a></li> <li role="presentation"><a href="?term=%22Neuropsychiatr%20Dis%20Treat%22%5Bjour%5D" class="usa-link" role="menuitem" data-add-to-search="true">Add to search</a></li> </ul></nav></section><section class="front-matter"><div class="ameta p font-secondary font-xs"> <hgroup><h1>Mifepristone (RU-486) treatment for depression and psychosis: a review of the therapeutic implications</h1></hgroup><div class="cg p"> <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Gallagher%20P%22%5BAuthor%5D" class="usa-link" aria-describedby="id1"><span class="name western">Peter Gallagher</span></a><div hidden="hidden" id="id1"> <h3><span class="name western">Peter Gallagher</span></h3> <div class="p"> <sup>1</sup>Stanley Research Centre, School of Neurology, Neurobiology and Psychiatry; University of Newcastle upon Tyne, UK</div> <div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Gallagher%20P%22%5BAuthor%5D" class="usa-link"><span class="name western">Peter Gallagher</span></a> </div> </div> <sup>1,</sup><sup>✉</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Young%20AH%22%5BAuthor%5D" class="usa-link" aria-describedby="id2"><span class="name western">Allan H Young</span></a><div hidden="hidden" id="id2"> <h3><span class="name western">Allan H Young</span></h3> <div class="p"> <sup>1</sup>Stanley Research Centre, School of Neurology, Neurobiology and Psychiatry; University of Newcastle upon Tyne, UK</div> <div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Young%20AH%22%5BAuthor%5D" class="usa-link"><span class="name western">Allan H Young</span></a> </div> </div> <sup>1</sup> </div> <ul class="d-buttons inline-list"> <li><button class="d-button" aria-controls="aip_a" aria-expanded="false">Author information</button></li> <li><button class="d-button" aria-controls="clp_a" aria-expanded="false">Copyright and License information</button></li> </ul> <div class="d-panels font-secondary-light"> <div id="aip_a" class="d-panel p" style="display: none"> <div class="p" id="af1-ndt-2-33"> <sup>1</sup>Stanley Research Centre, School of Neurology, Neurobiology and Psychiatry; University of Newcastle upon Tyne, UK</div> <div class="author-notes p"><div class="fn" id="c1-ndt-2-33"> <sup>✉</sup><p class="display-inline">Correspondence: Peter Gallagher, School of Neurology, Neurobiology and Psychiatry, University of Newcastle upon Tyne, Leazes Wing (Psychiatry), Royal Victoria Infirmary, Queen Victoria Road, Newcastle upon Tyne, NE1 4LP, UK, Tel + 44 191 282 4065, Fax + 44 191 222 6162, Email <span>peter.gallagher@ncl.ac.uk</span></p> </div></div> </div> <div id="clp_a" class="d-panel p" style="display: none"> <div>© 2006 Dove Medical Press Limited. All rights reserved</div> <div class="p"><a href="/about/copyright/" class="usa-link">PMC Copyright notice</a></div> </div> </div> <div>PMCID: PMC2671735 PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/19412444/" class="usa-link">19412444</a> </div> </div></section></section><section aria-label="Article content"><section class="body main-article-body"><section class="abstract" id="abstract1"><h2>Abstract</h2> <p>The mechanisms underlying the pathophysiology of severe psychiatric illnesses are complex, involving multiple neuronal and neurochemical pathways. A growing body of evidence indicates that alterations in hypothalamic–pituitary–adrenal (HPA) axis function may be a trait marker in both mood disorders and psychosis, and may exert significant causal and exacerbating effects on symptoms and neurocognition. At present, however, no available treatments preferentially target HPA axis abnormalities, although many drugs do increase feedback-regulation of the HPA axis at the level of the glucocorticoid receptor (GR). This action may in part underpin their therapeutic efficacy. Therapeutic interventions directly targeted at GR function may therefore have clinical benefit. The present review examines the current literature for the clinical utility of GR antagonists (specifically mifepristone) in mood disorders and psychosis. At present, most studies are at the “proof-of-concept” stage, although the results of preliminary, randomized, controlled trials are encouraging. The optimum strategy for the clinical application of GR antagonists is yet to be established, their potential role as first-line or adjunctive treatments being unclear. The therapeutic utility of such drugs will become known within the next few years following the results of larger clinical trials currently underway.</p> <section id="kwd-group1" class="kwd-group"><p><strong>Keywords:</strong> mifepristone, RU486, glucocorticoid receptor, cortisol, mood disorders, psychosis, treatment</p></section></section><section id="sec1"><h2 class="pmc_sec_title">Introduction</h2> <section id="sec2"><h3 class="pmc_sec_title">Overview</h3> <p>Dysfunction of the hypothalamic–pituitary–adrenal (HPA) axis has long been implicated in the pathogenesis and etiology of severe psychiatric illness. Studies have found evidence of reduced glucocorticoid receptor <strong>(</strong>GR) mRNA expression in post-mortem brain tissue samples from patients with mood disorders and psychosis (<a href="#b38-ndt-2-33" class="usa-link" aria-describedby="b38-ndt-2-33">Knable et al 2001</a>; <a href="#b81-ndt-2-33" class="usa-link" aria-describedby="b81-ndt-2-33">Webster et al 2002</a>; <a href="#b44-ndt-2-33" class="usa-link" aria-describedby="b44-ndt-2-33">Lopez et al 2003</a>). Many antidepressant drugs increase GR binding and/or number in brain tissue, suggesting that GR regulation may be one aspect of the therapeutic mechanism of action of antidepressants (and mood stabilizers), and the ability of a drug to regulate GR number may be a good predictor of therapeutic efficacy in patients with hypercortisolemia (<a href="#b48-ndt-2-33" class="usa-link" aria-describedby="b48-ndt-2-33">McQuade and Young 2000</a>). No drugs primarily or preferentially target the GR for use in psychiatry, although several are at present being examined for this purpose. The present review examines the current literature and proof-of-concept evidence for the clinical utility of GR antagonists (specifically mifepristone) in mood disorders and psychosis.</p></section><section id="sec3"><h3 class="pmc_sec_title">Search strategy</h3> <p>In order to include other antiglucocorticoid agents that specifically target the GR, the terms (“mifepristone” or “RU 486” or “RU 38486” or “ORG 34850”’ or “ORG 34116” or “ORG 34517”) were used in the initial search and combined with the terms (“mood disorders” or “psychosis” or “depression” or “bipolar disorder” or “schizophrenia”). The following databases were searched electronically: EMBASE (1980 to present), Medline (1966 to present), CINAHL (1982 to present), PsycINFO (1887 to present), and ISI Web of Science (1981 to present). Citation lists of relevant studies and reviews were checked for other relevant trials.</p></section></section><section id="sec4"><h2 class="pmc_sec_title">Background</h2> <section id="sec5"><h3 class="pmc_sec_title">The hypothalamic–pituitary–adrenal (HPA) axis</h3> <p>One of the major hormonal systems activated during stress is the HPA axis. Neurones in the paraventricular nucleus (PVN) of the hypothalamus secrete corticotrophin-releasing hormone (CRH) which is transported via the hypothalamo-pituitary portal circulation to the anterior pituitary where adrenocorticotropic hormone (ACTH) is secreted through stimulation of pituitary corticotrophs. ACTH then enters the peripheral circulation and stimulates the adrenal cortex to secrete glucocorticoids: corticosterone in rats, and cortisol in humans.</p> <p>Cortisol is essential for life. It is involved in the maintenance of glucose production from protein, facilitates fat metabolism, supports responsiveness of the vascular tree, modulates central nervous system function, and profoundly affects the immune system (<a href="#b7-ndt-2-33" class="usa-link" aria-describedby="b7-ndt-2-33">Berne and Levy 1998</a>). Importantly, it is a major regulator of the physiological stress response, through a negative feedback mechanism via corticosteroid receptors. Two distinct corticosteroid receptor subtypes have been identified: the mineralocorticoid receptor (MR; Type I) and the glucocorticoid receptor (GR; Type II). Both receptor types have been implicated in mediating glucocorticoid feedback (<a href="#b66-ndt-2-33" class="usa-link" aria-describedby="b66-ndt-2-33">Reul and de Kloet 1985</a>), but there are several differences in the distribution, occupancy, and binding properties of the two receptors that affect their physiological role.</p> <p>The MR is highly expressed in the limbic system whereas the GR is ubiquitous, being present in both subcortical and cortical structures, with a preferential distribution in the prefrontal cortex (<a href="#b61-ndt-2-33" class="usa-link" aria-describedby="b61-ndt-2-33">Patel et al 2000</a>). Glucocorticoids bind to the MR with 6–10 times higher affinity than to GR (<a href="#b14-ndt-2-33" class="usa-link" aria-describedby="b14-ndt-2-33">de Kloet et al 1999</a>). Consequently, at basal levels near complete occupation (~90%) of MRs occurs. GRs, however, are little occupied at this point (~10%), and only during times of high cortisol secretion, such as the circadian peak or during stress, do MRs become saturated and GR occupancy increases (to ~67%–74%) (<a href="#b66-ndt-2-33" class="usa-link" aria-describedby="b66-ndt-2-33">Reul and de Kloet 1985</a>). GR function is therefore critical in the regulation of the HPA axis at times of glucocorticoid excess and it is now recognized that disruption of this self-regulating system may be a major factor in the pathophysiology of mood disorders and psychosis.</p></section><section id="sec6"><h3 class="pmc_sec_title">The HPA axis in mood disorders and psychosis</h3> <p>The first observations of an elevation in basal cortisol levels in patients with depression were made almost half a century ago by Board and colleagues, and these observations have been repeatedly replicated (<a href="#b8-ndt-2-33" class="usa-link" aria-describedby="b8-ndt-2-33">Board et al 1956</a>; <a href="#b26-ndt-2-33" class="usa-link" aria-describedby="b26-ndt-2-33">Gibbons 1964</a>). It should be noted that the extent of HPA axis dysfunction differs by severity and subtype of depression. For example, a recent study found no evidence of hypercortisolism in women with major depression from a community-based setting (<a href="#b77-ndt-2-33" class="usa-link" aria-describedby="b77-ndt-2-33">Strickland et al 2002</a>), while pronounced HPA axis dysfunction has been described in depressed subjects with psychotic features (<a href="#b65-ndt-2-33" class="usa-link" aria-describedby="b65-ndt-2-33">Posener et al 2000</a>). The presence of psychosis may be related to hypercortisolism independently of mood symptoms (<a href="#b12-ndt-2-33" class="usa-link" aria-describedby="b12-ndt-2-33">Christie et al 1986</a>). Hypercortisolism has also been recognized in symptomatic schizophrenic patients (<a href="#b67-ndt-2-33" class="usa-link" aria-describedby="b67-ndt-2-33">Ritsner et al 2004</a>; <a href="#b69-ndt-2-33" class="usa-link" aria-describedby="b69-ndt-2-33">Ryan et al 2004</a>).</p> <p>Improvements in the methodology utilized has overcome some of the complexities surrounding the profiling of HPA axis dysfunction, revealing alterations in the diurnal pattern of cortisol secretion in depression (<a href="#b16-ndt-2-33" class="usa-link" aria-describedby="b16-ndt-2-33">Deuschle et al 1997</a>; <a href="#b65-ndt-2-33" class="usa-link" aria-describedby="b65-ndt-2-33">Posener et al 2000</a>), while employing less precise techniques such as total 24-hour cortisol output can fail to detect dysfunction (<a href="#b9-ndt-2-33" class="usa-link" aria-describedby="b9-ndt-2-33">Brouwer et al 2005</a>). Similarly, the measurement of the molar ratio of cortisol to other adrenal steroids can reveal differences – in the absence of hypercortisolism per se – in moderately depressed, non-psychotic outpatients (<a href="#b82-ndt-2-33" class="usa-link" aria-describedby="b82-ndt-2-33">Young et al 2002</a>). The most sensitive tests of HPA axis function, however, are “activating” tests, whereby neuroendocrine responses are measured following pharmacological challenge. These are preferred not only because of their increased sensitivity, but because they elucidate functional changes in the HPA axis at the receptor level.</p> <p>The GR agonist dexamethasone has been used widely to examine HPA axis negative feedback integrity (<a href="#b68-ndt-2-33" class="usa-link" aria-describedby="b68-ndt-2-33">Rush et al 1996</a>). An abnormal (nonsuppressed) cortisol response to dexamethasone administration has been described in schizophrenia (<a href="#b11-ndt-2-33" class="usa-link" aria-describedby="b11-ndt-2-33">Castro et al 1983</a>; <a href="#b50-ndt-2-33" class="usa-link" aria-describedby="b50-ndt-2-33">Muck-Seler et al 1999</a>) (but also see <a href="#b32-ndt-2-33" class="usa-link" aria-describedby="b32-ndt-2-33">Ismail et al 1998</a>) and mood disorders (<a href="#b68-ndt-2-33" class="usa-link" aria-describedby="b68-ndt-2-33">Rush et al 1996</a>), and may be exacerbated by psychotic features (<a href="#b18-ndt-2-33" class="usa-link" aria-describedby="b18-ndt-2-33">Duval et al 2000</a>). The combined dexamethasone–corticotrophin-releasing hormone (dex–CRH) test is also abnormal in bipolar patients during relapse and recovery (<a href="#b72-ndt-2-33" class="usa-link" aria-describedby="b72-ndt-2-33">Schmider et al 1995</a>; <a href="#b70-ndt-2-33" class="usa-link" aria-describedby="b70-ndt-2-33">Rybakowski and Twardowska 1999</a>; <a href="#b80-ndt-2-33" class="usa-link" aria-describedby="b80-ndt-2-33">Watson et al 2004</a>). Furthermore, GR abnormalities have been observed in post-mortem studies which show evidence of reduced GR mRNA expression in post-mortem brain tissue samples from patients with bipolar disorder and schizophrenia (<a href="#b38-ndt-2-33" class="usa-link" aria-describedby="b38-ndt-2-33">Knable et al 2001</a>; <a href="#b81-ndt-2-33" class="usa-link" aria-describedby="b81-ndt-2-33">Webster et al 2002</a>; <a href="#b44-ndt-2-33" class="usa-link" aria-describedby="b44-ndt-2-33">Lopez et al 2003</a>).</p></section><section id="sec7"><h3 class="pmc_sec_title">Consequences of HPA axis dysregulation and implications for treatment</h3> <p>Pronounced neurocognitive dysfunction is frequently described in mood disorder (<a href="#b63-ndt-2-33" class="usa-link" aria-describedby="b63-ndt-2-33">Porter et al 2003</a>; <a href="#b78-ndt-2-33" class="usa-link" aria-describedby="b78-ndt-2-33">Thompson et al 2005</a>); this may be worse in patients with psychotic features (<a href="#b21-ndt-2-33" class="usa-link" aria-describedby="b21-ndt-2-33">Fleming et al 2004</a>). In schizophrenia, the symptomatic clinical profile of the illness is complex and diverse, but neurocognitive impairment is consistently reported and some authors have argued that such impairments may be the cardinal feature of the illness (<a href="#b19-ndt-2-33" class="usa-link" aria-describedby="b19-ndt-2-33">Elvevag and Goldberg 2000</a>).</p> <p>Elevated levels of corticosteroids are known to impair learning and memory. This has been demonstrated by acute (<a href="#b45-ndt-2-33" class="usa-link" aria-describedby="b45-ndt-2-33">Lupien and McEwen 1997</a>; <a href="#b49-ndt-2-33" class="usa-link" aria-describedby="b49-ndt-2-33">Modell et al 1997</a>) and subchronic (<a href="#b84-ndt-2-33" class="usa-link" aria-describedby="b84-ndt-2-33">Young et al 1999</a>) administration of exogenous corticosteroids in healthy volunteers and in conditions associated with a chronic elevation of endogenous cortisol levels, for example Cushing’s disease (<a href="#b76-ndt-2-33" class="usa-link" aria-describedby="b76-ndt-2-33">Starkman et al 2001</a>; <a href="#b23-ndt-2-33" class="usa-link" aria-describedby="b23-ndt-2-33">Forget et al 2002</a>), which is also associated with a high incidence of depression that notably resolves with correction of the hypercortisolemia (<a href="#b17-ndt-2-33" class="usa-link" aria-describedby="b17-ndt-2-33">Dorn et al 1997</a>). Patients receiving systemic corticosteroid therapy also often exhibit cognitive impairment and, in some instances, symptoms of (hypo)mania, depression, and psychosis (<a href="#b10-ndt-2-33" class="usa-link" aria-describedby="b10-ndt-2-33">Brown and Chandler 2001</a>). HPA axis dysregulation therefore has been suggested to be one of the principal causes of both low mood and neurocognitive impairment, possibly through interactions with other neurotransmitter system (<a href="#b47-ndt-2-33" class="usa-link" aria-describedby="b47-ndt-2-33">McAllister-Williams et al 1998</a>; <a href="#b64-ndt-2-33" class="usa-link" aria-describedby="b64-ndt-2-33">Porter et al 2004</a>).</p> <p>The known consequences of hypercortisolemia on neurocognitive function and mood, and the central role of corticosteroid receptors in HPA axis regulation, therefore indicate a possible use for antiglucocorticoid drugs and make the GR specifically a potentially viable target for therapeutic intervention.</p></section></section><section id="sec8"><h2 class="pmc_sec_title">Mifepristone (RU-486)</h2> <section id="sec9"><h3 class="pmc_sec_title">Discovery and development</h3> <p>Mifepristone (or RU-486) is a synthetic steroid with both antiprogesterone and antiglucocorticoid properties. The compound is a 19-nor steroid with substitutions at positions C11 and C17 (17 beta-hydroxy-11 beta-[4-dimethylamino phenyl] 17 alpha-[1-propynyl]estra-4,9-dien-3-one) which antagonizes cortisol action competitively at the receptor level (<a href="#b52-ndt-2-33" class="usa-link" aria-describedby="b52-ndt-2-33">Nieman et al 1985</a>). It was discovered in the early 1980s by the French pharmaceutical company Roussel–Uclaf (<a href="#b29-ndt-2-33" class="usa-link" aria-describedby="b29-ndt-2-33">Herrmann et al 1982</a>; <a href="#b34-ndt-2-33" class="usa-link" aria-describedby="b34-ndt-2-33">Jung-Testas and Baulieu 1983</a>). At present it is licenced in the UK for the medical termination of pregnancy (trade name: Mifegyne<sup>®</sup>; marketing authorization holder: Exelgyn Laboratories, Paris, France). Mifepristone was the first antiprogestin to be developed and it has been evaluated extensively for its use as an abortifacient. The original target for the research group, however, was the discovery and development of compounds with antiglucocorticoid properties (<a href="#b28-ndt-2-33" class="usa-link" aria-describedby="b28-ndt-2-33">Hazra and Pore 2001</a>), and it is these properties that are of greatest interest for their application in the treatment of severe mood disorders and psychosis.</p></section><section id="sec10"><h3 class="pmc_sec_title">Pharmacokinetics and pharmacodynamic activity</h3> <p>The pharmacokinetics of mifepristone are dose-dependent in humans (<a href="#b1-ndt-2-33" class="usa-link" aria-describedby="b1-ndt-2-33">Ashok et al 2002</a>). Due to saturation of the serum-binding capacity, high-dose mifepristone results in nonlinear kinetics, whereas lower doses show a linear pattern (<a href="#b43-ndt-2-33" class="usa-link" aria-describedby="b43-ndt-2-33">Leminen et al 2003</a>). For example, following administration of doses of 50–800 mg, after the absorption and distribution phase of approximately 4–6 hours, the serum concentration of mifepristone remains in the micromolar range for the next 24–48 hours. Within the dose range of 2–25 mg, serum concentrations of mifepristone, as well as the areas under the concentration–time curves (AUC), increase according to dose (<a href="#b74-ndt-2-33" class="usa-link" aria-describedby="b74-ndt-2-33">Sitruk-Ware and Spitz 2003</a>).</p> <p>Following a single oral dose of 600 mg mifepristone, the binding equivalent is present in measurable concentrations 7 days after administration, only decreasing below assay detection limits >7–14 days (<a href="#b22-ndt-2-33" class="usa-link" aria-describedby="b22-ndt-2-33">Foldesi et al 1996</a>). In this study, the concentration of the mifepristone binding equivalent reached a peak within approximately 2 hours (doses 200–600 mg), indicating rapid absorption. Peak levels were significantly greater following the 600 mg dose (C<sub>max</sub> = 12.3 μmol/L vs 200 mg: 6.30 μmol/L), while the bioavailability as assessed by the AUC was significantly greater following 600 mg dose than both 200 and 400 mg. These were not, however, directly proportional to the dose increase (<a href="#b22-ndt-2-33" class="usa-link" aria-describedby="b22-ndt-2-33">Foldesi et al 1996</a>).</p> <p>In contrast to mifepristone plasma concentrations, plasma concentrations of its metabolites do increase in a dose-dependent manner when larger doses are administered, so that serum metabolite concentrations are close to, or even in excess of, those of the parent compound (<a href="#b41-ndt-2-33" class="usa-link" aria-describedby="b41-ndt-2-33">Lahteenmaki et al 1987</a>). These metabolites have some antiprogestin and antiglucocorticoid properties, and therefore may mediate some of the actions of mifepristone (<a href="#b75-ndt-2-33" class="usa-link" aria-describedby="b75-ndt-2-33">Spitz and Bardin 1993</a>).</p></section><section id="sec11"><h3 class="pmc_sec_title">Side effects of chronic mifepristone administration</h3> <p>Laue and colleagues reported that in healthy male normal volunteers who received mifepristone (10 mg/kg/day), 8 of 11 subjects developed generalized exanthem after 9 days. One subject developed symptoms and signs consistent with the diagnosis of adrenal insufficiency (<a href="#b42-ndt-2-33" class="usa-link" aria-describedby="b42-ndt-2-33">Laue et al 1990</a>). For immune function, it was reported that total white blood cell counts, absolute lymphocyte, neutrophil, and eosinophil counts, erythrocyte sedimentation rate, and quantitative immunoglobulins did not change. Similarly, T-, B-, and natural killer cell subsets did not change during treatment. Furthermore, functional evaluation of lymphocyte cytotoxicity and proliferation revealed no changes.</p> <p>A study using lower doses (200 mg/day for 2 to > 31 months) in 14 patients with unresectable meningiomas reported milder side effects. Most commonly, fatigue was noted in 11 of the 14 patients (<a href="#b27-ndt-2-33" class="usa-link" aria-describedby="b27-ndt-2-33">Grunberg et al 1991</a>). However, in a study of mifepristone (200 mg/day for up to 8 weeks) in chronic depression, 1 of 4 patients discontinued treatment prematurely because of the appearance of a rash (<a href="#b51-ndt-2-33" class="usa-link" aria-describedby="b51-ndt-2-33">Murphy et al 1993</a>). In patients with psychotic depression receiving mifepristone (50–1200 mg/day for 7 days), 2 of 10 patients in the 600-mg group and 1 of 9 in the 1200-mg group reported uterine cramping, while 1 of 11 patients in the 50-mg group and 1 of 9 patients in the 1200-mg group (but none in the 600-mg group) reported a rash. In both cases, this had abated 1–2 months after study completion (<a href="#b6-ndt-2-33" class="usa-link" aria-describedby="b6-ndt-2-33">Belanoff et al 2002</a>).</p></section><section id="sec12"><h3 class="pmc_sec_title">Antiglucocorticoid effects of mifepristone</h3> <p>A large amount of human clinical data on the antiglucocorticoid actions of mifepristone have come from studies in Cushing’s disease (<a href="#b71-ndt-2-33" class="usa-link" aria-describedby="b71-ndt-2-33">Sartor and Cutler 1996</a>). Nieman and colleagues administered mifepristone orally at increasing doses of 5, 10, 15, and 20 mg/kg/day for a 9-week period to a patient with Cushing’s syndrome due to ectopic ACTH secretion. Following treatment, the somatic features associated with Cushing’s syndrome ameliorated and blood pressure normalized. Importantly, suicidal ideation and depression also resolved, and all biochemical glucocorticoid-sensitive parameters normalized (<a href="#b52-ndt-2-33" class="usa-link" aria-describedby="b52-ndt-2-33">Nieman et al 1985</a>).</p> <p>Mifepristone has also been shown to rapidly reverse acute psychosis in Cushing’s syndrome (<a href="#b79-ndt-2-33" class="usa-link" aria-describedby="b79-ndt-2-33">van der Lely et al 1991</a>). More recently, high-dose (up to 25 mg/kg/day), long-term mifepristone administration was shown to normalize all biochemical glucocorticoid-sensitive measurements, as well as significantly reverse psychotic depression in a patient with Cushing’s syndrome caused by an ACTH-secreting pituitary macroadenoma (<a href="#b13-ndt-2-33" class="usa-link" aria-describedby="b13-ndt-2-33">Chu et al 2001</a>). Although the adrenal axis also normalized, the 18-month-long mifepristone treatment course led to the development of severe hypokalemia (attributed to excessive cortisol activation of MRs), which responded to spironolactone administration.</p></section></section><section id="sec13"><h2 class="pmc_sec_title">Use of mifepristone in mood disorders and psychosis (<a href="#t1-ndt-2-33" class="usa-link">Table 1</a>)</h2> <section class="tw xbox font-sm" id="t1-ndt-2-33"><h3 class="obj_head">Table 1.</h3> <div class="caption p"><p>Studies of glucocorticoid receptor antagonists in mood disorders and psychosis (see text for further details)</p></div> <div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups"> <thead><tr> <th align="left" rowspan="1" colspan="1">Study</th> <th align="left" rowspan="1" colspan="1">Drug</th> <th align="left" rowspan="1" colspan="1">Dose</th> <th align="left" rowspan="1" colspan="1">Study design</th> <th align="right" rowspan="1" colspan="1">N</th> <th align="left" rowspan="1" colspan="1">Patient group</th> <th align="left" rowspan="1" colspan="1">Concomitant medications</th> <th align="left" rowspan="1" colspan="1">Effects on symptoms</th> <th align="left" rowspan="1" colspan="1">Effects on neurocognitive function</th> </tr></thead> <tbody> <tr> <td align="left" rowspan="1" colspan="1">(<a href="#b37-ndt-2-33" class="usa-link" aria-describedby="b37-ndt-2-33">Kling et al 1989</a>)</td> <td align="left" rowspan="1" colspan="1">Mifepristone</td> <td align="left" rowspan="1" colspan="1">10 mg/kg single dose</td> <td align="left" rowspan="1" colspan="1"> <a href="#tfn1-ndt-2-33" class="usa-link"><sup>a</sup></a> Experimental</td> <td align="right" rowspan="1" colspan="1">8</td> <td align="left" rowspan="1" colspan="1">MDD</td> <td align="left" rowspan="1" colspan="1">Drug-free (2 weeks)</td> <td align="left" rowspan="1" colspan="1">n/a</td> <td align="left" rowspan="1" colspan="1">n/a</td> </tr> <tr> <td align="left" rowspan="1" colspan="1">(<a href="#b39-ndt-2-33" class="usa-link" aria-describedby="b39-ndt-2-33">Krishnan et al 1992</a>)</td> <td align="left" rowspan="1" colspan="1">Mifepristone</td> <td align="left" rowspan="1" colspan="1">400 mg single dose</td> <td align="left" rowspan="1" colspan="1"> <a href="#tfn1-ndt-2-33" class="usa-link"><sup>a</sup></a> Experimental</td> <td align="right" rowspan="1" colspan="1">7</td> <td align="left" rowspan="1" colspan="1">MDD</td> <td align="left" rowspan="1" colspan="1">Drug-free (1 week)</td> <td align="left" rowspan="1" colspan="1">n/a</td> <td align="left" rowspan="1" colspan="1">n/a</td> </tr> <tr> <td align="left" rowspan="1" colspan="1">(<a href="#b51-ndt-2-33" class="usa-link" aria-describedby="b51-ndt-2-33">Murphy et al 1993</a>)</td> <td align="left" rowspan="1" colspan="1">Mifepristone</td> <td align="left" rowspan="1" colspan="1">200 mg/day, up to 8 weeks</td> <td align="left" rowspan="1" colspan="1">Open-label</td> <td align="right" rowspan="1" colspan="1">4</td> <td align="left" rowspan="1" colspan="1">MDD</td> <td align="left" rowspan="1" colspan="1">Drug-free; benzodiazepines and acetaminophen permitted</td> <td align="left" rowspan="1" colspan="1">HDRS scores decreased between 16% and 66% for all patients.</td> <td align="left" rowspan="1" colspan="1">n/a</td> </tr> <tr> <td align="left" rowspan="1" colspan="1">(<a href="#b31-ndt-2-33" class="usa-link" aria-describedby="b31-ndt-2-33">Høyberg et al 2002</a>)</td> <td align="left" rowspan="1" colspan="1">ORG34517</td> <td align="left" rowspan="1" colspan="1">150– 300 mg/day, 450– 600 mg/day, up to 4 weeks</td> <td align="left" rowspan="1" colspan="1">Double-blind, randomized, paroxetine controlled</td> <td align="right" rowspan="1" colspan="1">142</td> <td align="left" rowspan="1" colspan="1">MDD</td> <td align="left" rowspan="1" colspan="1">Drug-free; benzodiazepines permitted</td> <td align="left" rowspan="1" colspan="1">All groups improved. Larger improvement from baseline in low- dose ORG group at day 10. Patients reaching full remission significantly higher in low- than both the high-dose and paroxetine-treated groups (39.1% vs 20.5% and 31.0% respectively).</td> <td align="left" rowspan="1" colspan="1">n/a</td> </tr> <tr> <td align="left" rowspan="1" colspan="1">(<a href="#b5-ndt-2-33" class="usa-link" aria-describedby="b5-ndt-2-33">Belanoff et al 2001</a>)</td> <td align="left" rowspan="1" colspan="1">Mifepristone</td> <td align="left" rowspan="1" colspan="1">600 mg/day, 4 days</td> <td align="left" rowspan="1" colspan="1">Double-blind, placebo controlled, crossover</td> <td align="right" rowspan="1" colspan="1">5</td> <td align="left" rowspan="1" colspan="1">Psychotic MDD</td> <td align="left" rowspan="1" colspan="1">Antipsychotic free (3 days); benzodiazepines and acetaminophen permitted</td> <td align="left" rowspan="1" colspan="1">HDRS scores declined during mifepristone treatment in all patients. BPRS scores declined in 4 of 5 patients.</td> <td align="left" rowspan="1" colspan="1">n/a</td> </tr> <tr> <td align="left" rowspan="1" colspan="1">(<a href="#b6-ndt-2-33" class="usa-link" aria-describedby="b6-ndt-2-33">Belanoff et al 2002</a>)</td> <td align="left" rowspan="1" colspan="1">Mifepristone 1200 mg/day, 7 days</td> <td align="left" rowspan="1" colspan="1">50, 600,</td> <td align="left" rowspan="1" colspan="1">Open-label</td> <td align="right" rowspan="1" colspan="1">30</td> <td align="left" rowspan="1" colspan="1">Psychotic MDD</td> <td align="left" rowspan="1" colspan="1">Stable for 1 week prior</td> <td align="left" rowspan="1" colspan="1">HDRS response by dose in 2/11 (18.2%) 5/10, (50%), 3/9 (33%) patients respectively. BPRS response in 4/11 (36.4%), 7/10 (70%), 6/9 (66.7%) respectively.</td> <td align="left" rowspan="1" colspan="1">n/a</td> </tr> <tr> <td align="left" rowspan="1" colspan="1">(<a href="#b73-ndt-2-33" class="usa-link" aria-describedby="b73-ndt-2-33">Simpson et al 2005</a>)</td> <td align="left" rowspan="1" colspan="1">Mifepristone</td> <td align="left" rowspan="1" colspan="1">200 mg tid, 6 days</td> <td align="left" rowspan="1" colspan="1">Open-label</td> <td align="right" rowspan="1" colspan="1">20</td> <td align="left" rowspan="1" colspan="1">Psychotic MDD</td> <td align="left" rowspan="1" colspan="1">Drug-free (1 week) except for lorazepam</td> <td align="left" rowspan="1" colspan="1">CGI and HDRS improved after week 1, and between week 1 to 4. BPRS improved after week 4</td> <td align="left" rowspan="1" colspan="1">n/a</td> </tr> <tr> <td align="left" rowspan="1" colspan="1">(<a href="#b83-ndt-2-33" class="usa-link" aria-describedby="b83-ndt-2-33">Young et al 2004</a>)</td> <td align="left" rowspan="1" colspan="1">Mifepristone</td> <td align="left" rowspan="1" colspan="1">600 mg/day, 7 days</td> <td align="left" rowspan="1" colspan="1">Double-blind, placebo controlled RCT</td> <td align="right" rowspan="1" colspan="1">20</td> <td align="left" rowspan="1" colspan="1">Bipolar disorder (depressed)</td> <td align="left" rowspan="1" colspan="1">Stable for 6 weeks prior</td> <td align="left" rowspan="1" colspan="1">HDRS (5.1 points), MADRS (6 points), BPRS (4 points) improved from baseline at day 14 with active drug.</td> <td align="left" rowspan="1" colspan="1">SWM improved 19.8% over placebo at day 21. Spatial recognition, verbal fluency improved from baseline following active drug.</td> </tr> <tr> <td align="left" rowspan="1" colspan="1">(<a href="#b24-ndt-2-33" class="usa-link" aria-describedby="b24-ndt-2-33">Gallagher et al 2005</a>)</td> <td align="left" rowspan="1" colspan="1">Mifepristone</td> <td align="left" rowspan="1" colspan="1">600 mg/day, 7 days</td> <td align="left" rowspan="1" colspan="1">Double-blind, placebo controlled RCT</td> <td align="right" rowspan="1" colspan="1">20</td> <td align="left" rowspan="1" colspan="1">Schizophrenia (chronic, symptomatic)</td> <td align="left" rowspan="1" colspan="1">Stable for 6 weeks prior</td> <td align="left" rowspan="1" colspan="1">No effect on BPRS or Calgary. Improvements in HDRS and MADRS in both arms of the study (nonspecific effect).</td> <td align="left" rowspan="1" colspan="1">No effect</td> </tr> </tbody> </table></div> <div class="p text-right font-secondary"><a href="table/t1-ndt-2-33/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div> <div class="tw-foot p"> <div class="fn" id="tfn1-ndt-2-33"> <sup>a</sup><p class="display-inline">These studies examined HPA axis responses only.</p> </div> <div class="fn" id="tfn2-ndt-2-33"><p><strong>Abbreviations:</strong> BPRS, Brief Psychiatric Rating Scale; Calgary, Calgary Depression Scale; CGI, Clinical Global Impression; HDRS, Hamilton Depression Rating Scale; HPA, hypothalamic–pituitary–adrenal; MADRS, Montgomery-Åsberg Depression Rating Scale; MDD, Major Depressive Disorder; n/a, not assessed; RCT, randomized clinical trial; SWM, Spatial Working Memory (CANTAB); tid, three times daily.</p></div> </div></section><p>Early work highlighted the potential for antiglucocorticoid strategies in depression. Initially the focus of studies utilizing mifepristone was on the effect on endocrine parameters (<a href="#b37-ndt-2-33" class="usa-link" aria-describedby="b37-ndt-2-33">Kling et al 1989</a>; <a href="#b39-ndt-2-33" class="usa-link" aria-describedby="b39-ndt-2-33">Krishnan et al 1992</a>). In the first open trial of mifepristone treatment of major depression, Murphy and colleagues administered mifepristone (200 mg each morning) for as long as it was tolerated, for up to 8 weeks to 4 patients with “drug-resistant” depression. Data were presented as a case-series and showed improvements of between 16% and 66% on the Hamilton Depression Rating Scale (HDRS) (<a href="#b51-ndt-2-33" class="usa-link" aria-describedby="b51-ndt-2-33">Murphy et al 1993</a>). The trial terminated, however, due to problems obtaining the trial medication (the supplier cancelled the contract).</p> <p>Recent studies have renewed interest in the potential therapeutic efficacy of GR antagonists in the treatment of mood disorders and psychosis.</p> <section id="sec14"><h3 class="pmc_sec_title">Psychotic depression</h3> <p>In a double-blind, placebo-controlled crossover case-series in 5 patients with psychotic depression, Belanoff and colleagues found a rapid improvement in depression ratings and psychotic symptoms following 4 days’ treatment with mifepristone (<a href="#b5-ndt-2-33" class="usa-link" aria-describedby="b5-ndt-2-33">Belanoff et al 2001</a>). Subsequently they have replicated these findings in an open-label study in 30 psychotic depressed patients (<a href="#b6-ndt-2-33" class="usa-link" aria-describedby="b6-ndt-2-33">Belanoff et al 2002</a>). Patients received mifepristone, either 50 mg/day (n = 11), 600 mg/day (n = 10), or 1200 mg/day (n = 9) for 7 days. Criteria for response were defined as a 50% reduction on the Hamilton Rating Scale for Depression-21 (HAMD-21), a 30% reduction on the Brief Psychiatric Rating Scale (BPRS), and a 50% reduction on the BPRS positive symptom subscale. Using these criteria, respectively, it was found that 18.2%, 36.4%, and 27.3% of patients responded to 50 mg/day; 50%, 70%, and 60% responded to 600 mg/day, and 33%, 66.7%, and 66.7% responded to 1200 mg/day. The results of this study also suggested that high-dose treatment (≥ 600 mg) for short periods (≤ 7 days) was the optimal method of administration.</p> <p>A second trial has been carried out recently with a longer follow-up period (<a href="#b73-ndt-2-33" class="usa-link" aria-describedby="b73-ndt-2-33">Simpson et al 2005</a>). Twenty MDD patients (with psychotic features) were treated with mifepristone 200 mg 3 times daily, open-label for 6 days. All patients had been psychotropic medication-free (except lorazepam for sleep) for at least 1 week prior to baseline ratings. Significant improvements in HDRS and Clinical Global Impression (CGI) scores were observed in the group (from baseline) after 1 week and between weeks 1 and 4. This effect remained stable to follow-up at 8 weeks. BPRS scores also improved after week 4. A number of patients did not complete the trial, however, because of good clinical response (discharged and lost to follow-up) or nonresponse (alternative clinical intervention required).</p> <p>Preliminary communications have also been made on the results of larger trials (n > 200) of mifepristone in psychotic depression (<a href="#b4-ndt-2-33" class="usa-link" aria-describedby="b4-ndt-2-33">Belanoff and DeBattista 2004</a>; <a href="#b15-ndt-2-33" class="usa-link" aria-describedby="b15-ndt-2-33">DeBattista and Belanoff 2004</a>). These studies suggest that the effect on psychotic symptoms, particularly, may be rapid and persistent. The publication of these results is awaited and will provide clearer data on the efficacy of GR antagonists in this condition.</p></section><section id="sec15"><h3 class="pmc_sec_title">Bipolar disorder</h3> <p>We have recently completed the first proof-of-concept study on the use of GR antagonists in the treatment of bipolar depression, in a double-blind, placebo-controlled crossover design (<a href="#b83-ndt-2-33" class="usa-link" aria-describedby="b83-ndt-2-33">Young et al 2004</a>). We hypothesized that mifepristone (administered adjunctively to existing medication) would improve neurocognitive function and attenuate depressive symptoms in this disorder. Twenty patients, ages 18 to 65, with a diagnosis of bipolar depression (confirmed using the Structured Clinical Interview for DSM-IV; SCID [<a href="#b20-ndt-2-33" class="usa-link" aria-describedby="b20-ndt-2-33">First et al 1995</a>]) and residual depressive symptoms were recruited. Patients’ medication had been unchanged for 6 weeks prior to participation and remained so throughout the study period.</p> <p>On the basis of previous research, it was predicted that the principal cognitive domains that would be most sensitive to changes in HPA axis function were working memory and verbal declarative memory. Neurocognitive tests were therefore administered to explore these domains. Following treatment with mifepristone, selective improvement in neurocognitive functioning was observed. Spatial working memory performance was significantly improved compared with placebo (19.8% improvement over placebo). Measures of verbal fluency and spatial recognition memory also significantly improved from baseline levels after mifepristone. No significant change occurred after placebo.</p> <p>Beneficial effects on mood were found; HDRS scores were significantly reduced compared with baseline (mean reduction of 5.1 points) as were Montgomery–Åsberg Depression Rating Scale scores (mean reduction of 6.05 points). No significant change occurred after placebo. Furthermore, baseline cortisol output correlated positively with the percentage improvement in spatial working memory error rate following mifepristone administration.</p></section><section id="sec16"><h3 class="pmc_sec_title">Schizophrenia</h3> <p>Utilizing the same experimental design as described above (<a href="#b83-ndt-2-33" class="usa-link" aria-describedby="b83-ndt-2-33">Young et al 2004</a>), we have recently completed the first trial to examine the efficacy of adjunctive mifepristone administration in schizophrenia (<a href="#b24-ndt-2-33" class="usa-link" aria-describedby="b24-ndt-2-33">Gallagher et al 2005</a>). In contrast to the findings on bipolar disorder, mifepristone had no significant effect on symptoms or neurocognitive functioning despite a pronounced effect on the HPA axis. There are several possible explanations for this discrepancy. As described above, mifepristone has been shown to have some positive effects on depressive symptoms in bipolar disorder as well as on psychosis in psychotic major depression. Also, the effects of mifepristone were more pronounced on neurocognitive function in bipolar patients. This may suggest that affective symptoms or affective psychosis may be modulated primarily by the HPA axis and that neurocognitive dysfunction in mood disorders is steroid-dependent and a consequence of HPA axis dysregulation, whereas in schizophrenia these may be attributable to different underlying neurobiological abnormalities.</p> <p>Alternatively, it may be that the schizophrenic patients recruited in this study did not have an abnormal HPA axis at baseline. There is some evidence that the chronicity of psychotic illness directly affects the neurobiology of the HPA axis. <a href="#b59-ndt-2-33" class="usa-link" aria-describedby="b59-ndt-2-33">Pariante and colleagues (2004)</a> found that first-episode psychosis was associated with a larger pituitary volume, which was suggested to be a consequence of activation of the HPA axis. In “established” schizophrenia (such as in the population in our study), smaller pituitary volume was observed (<a href="#b60-ndt-2-33" class="usa-link" aria-describedby="b60-ndt-2-33">Pariante et al 2004b</a>). Therefore, the schizophrenic patients may not respond to a GR antagonist in the same manner as patients with affective illnesses.</p></section><section id="sec17"><h3 class="pmc_sec_title">Other GR antagonists</h3> <p>ORG 34517 was designed as a specific antiglucocorticoid to selectively target the GR. A preliminary report comparing low- and high-dose ORG 34517 administration and paroxetine found that all treatment groups showed improvements in HDRS scores over the 4-week treatment period (<a href="#b31-ndt-2-33" class="usa-link" aria-describedby="b31-ndt-2-33">Høyberg et al 2002</a>). Low-dose ORG 34517 appeared to increase the speed of response, however, HDRS scores being significantly lower (from baseline) than both other treatment arms by day 10 of the trial. This effect was greater in subjects with a higher degree of HPA axis dysfunction. The proportion of subjects in full remission by the end of the trial was also significantly greater than the proportion of both the high-dose and paroxetine-treated groups (39.1% vs 20.5% and 31.0% respectively).</p></section></section><section id="sec18"><h2 class="pmc_sec_title">Mechanisms of action</h2> <section id="sec19"><h3 class="pmc_sec_title">Corticosteroid receptor imbalance</h3> <p>The mechanism through which mifepristone may be exerting effects on symptoms and neurocognitive function is unclear. It has been suggested that by blocking the GR a “resetting” of the HPA axis may occur (<a href="#b6-ndt-2-33" class="usa-link" aria-describedby="b6-ndt-2-33">Belanoff et al 2002</a>). Interestingly, animal work has shown that in comparison with other selective GR antagonists, mifepristone was the only compound to increase GR binding in the frontal cortex, although an increase in MR binding was also observed (<a href="#b2-ndt-2-33" class="usa-link" aria-describedby="b2-ndt-2-33">Bachmann et al 2003</a>). In the neocortex, however, mifepristone selectively decreased MR binding.</p> <p>GR integrity has consistently been shown to be lowered in patients with severe psychiatric disorders both functionally, using the DST (<a href="#b68-ndt-2-33" class="usa-link" aria-describedby="b68-ndt-2-33">Rush et al 1996</a>), and structurally, with reduced GR mRNA expression in postmortem brain tissue samples (<a href="#b81-ndt-2-33" class="usa-link" aria-describedby="b81-ndt-2-33">Webster et al 2002</a>). There is some evidence, however, that MR function may be normal or even enhanced in mood disorders (<a href="#b85-ndt-2-33" class="usa-link" aria-describedby="b85-ndt-2-33">Young et al 2003</a>). Although speculative, some of the therapeutic actions of mifepristone may operate through the ability of the drug to modulate corticosteroid receptor balance (ie, exposing brain MR to the elevated cortisol levels caused by GR blockade). This may be particularly so for neurocognitive functioning, which depends on the relative ratio of corticosteroid receptor occupancy (<a href="#b45-ndt-2-33" class="usa-link" aria-describedby="b45-ndt-2-33">Lupien and McEwen 1997</a>).</p></section><section id="sec20"><h3 class="pmc_sec_title">Transport of cortisol into the brain</h3> <p>Recent work has shown that many antidepressant drugs have actions on blood-brain barrier steroid transporters (such as multidrug resistance p-glycoprotein). Plasma cortisol cannot freely enter the brain by passive diffusion because its access is limited by such membrane steroid transporters which actively expel cortisol from the brain. It has been suggested that some antidepressants may inhibit membrane steroid transporters at the blood–brain barrier and in neurones, so that more cortisol is able to enter the brain (<a href="#b58-ndt-2-33" class="usa-link" aria-describedby="b58-ndt-2-33">Pariante 2004</a>; <a href="#b59-ndt-2-33" class="usa-link" aria-describedby="b59-ndt-2-33">Pariante et al 2004a</a>), thereby restoring glucocorticoid-mediated negative feedback of the HPA axis (<a href="#b59-ndt-2-33" class="usa-link" aria-describedby="b59-ndt-2-33">Pariante et al 2004a</a>). Hypercortisolemia is therefore argued to be a possible compensatory adaptive response to a central <em>hypo</em>cortisolemic state (<a href="#b57-ndt-2-33" class="usa-link" aria-describedby="b57-ndt-2-33">Pariante 2003</a>). Considering mifepristone: the antagonist action of mifepristone on GR causes a robust (2- to 3-fold) elevation in cortisol levels and this may facilitate HPA axis negative feedback. Certainly, this may be the case when mifepristone is administered adjunctively with other antidepressant medications (see above). This mechanism may underlie some of the clinical benefits of the drug.</p></section><section id="sec21"><h3 class="pmc_sec_title">Speed of response</h3> <p>One notable characteristic of antiglucocorticoid strategies in studies to date is that they appear to initiate a rapid, short-term clinical response. The study of the ORG 34517 by Høyberg and colleagues in medication-free patients with major depression showed that differences between treatment arms emerged after day 7 of the trial, with significant benefits being observed at day 10–14. This was especially pronounced in patients with clearly defined HPA axis abnormalities. After this time, response rates were approximately equivalent (<a href="#b31-ndt-2-33" class="usa-link" aria-describedby="b31-ndt-2-33">Høyberg et al 2002</a>). Rapid responses have also been observed following mifepristone administration in psychotic depression (<a href="#b5-ndt-2-33" class="usa-link" aria-describedby="b5-ndt-2-33">Belanoff et al 2001</a>; <a href="#b6-ndt-2-33" class="usa-link" aria-describedby="b6-ndt-2-33">Belanoff et al 2002</a>; <a href="#b73-ndt-2-33" class="usa-link" aria-describedby="b73-ndt-2-33">Simpson et al 2005</a>).</p> <p>Alternative antiglucocorticoid strategies such as cortisol synthesis inhibition similarly alter the course of clinical response. Jahn and colleagues administered metyrapone or placebo to 63 (psychotropic) medication-free patients with major depression. A higher proportion of patients receiving metyrapone showed a positive treatment response, but importantly the response began within a week of initiation of treatment, suggesting an earlier onset of action (<a href="#b33-ndt-2-33" class="usa-link" aria-describedby="b33-ndt-2-33">Jahn et al 2004</a>).</p> <p>The ability of such drugs to rapidly improve treatment response suggests that they may be used either to increase efficacy of treatment regimens in medicated patients or initiate a response that can be maintained with conventional treatments. The optimum strategy for the clinical application of GR antagonists has yet to be established, with their potential role as either first-line or adjunctive treatments being unclear.</p></section><section id="sec22"><h3 class="pmc_sec_title">Effects on neurocognitive function</h3> <p>Although few studies to date have examined the neuro-cognitive effects, mifepristone may be efficacious in this respect in mood disorder.</p> <p>In a recent study in rats, mifepristone was the only GR antagonist examined to increase both MR and GR binding in the frontal cortex (<a href="#b2-ndt-2-33" class="usa-link" aria-describedby="b2-ndt-2-33">Bachmann et al 2003</a>). This may underpin the selective pattern of improvement in neuro-cognitive function seen in our study (<a href="#b83-ndt-2-33" class="usa-link" aria-describedby="b83-ndt-2-33">Young et al 2004</a>), which was restricted to tests that have been shown to be sensitive to frontal lobe dysfunction. Oitzl and colleagues have shown that mifepristone (RU-38486) injected locally into the dorsal hippocampus dose-dependently improved the performance of male Wistar rats in the water maze 24 hours after treatment (<a href="#b53-ndt-2-33" class="usa-link" aria-describedby="b53-ndt-2-33">Oitzl et al 1998a</a>). Importantly, opposing effects on spatial memory have been shown to occur after either phasic or continuous blockade of brain GR by intracerebroventricular administration of mifepristone. Phasic blockade was found to dose-dependently impair spatial memory (Morris water maze), examined after a daily pretraining administration, whereas continuous GR blockade resulted in a long-lasting facilitation of spatial performance (<a href="#b54-ndt-2-33" class="usa-link" aria-describedby="b54-ndt-2-33">Oitzl et al 1998b</a>). In humans, aspects of spatial memory are affected in various degrees in patients with hippocampal lesions (<a href="#b35-ndt-2-33" class="usa-link" aria-describedby="b35-ndt-2-33">Kessels et al 2001</a>), some tasks such as (spatial) working memory being more dependent on the integrity of the frontal lobes (<a href="#b56-ndt-2-33" class="usa-link" aria-describedby="b56-ndt-2-33">Owen et al 1995</a>; <a href="#b55-ndt-2-33" class="usa-link" aria-describedby="b55-ndt-2-33">Owen et al 1996</a>; <a href="#b36-ndt-2-33" class="usa-link" aria-describedby="b36-ndt-2-33">Kessels et al 2000</a>; <a href="#b35-ndt-2-33" class="usa-link" aria-describedby="b35-ndt-2-33">Kessels et al 2001</a>). Consequently, the effects of mifepristone on corticosteroid receptor expression may explain the observed pattern of neurocognitive improvement observed in studies to date.</p></section><section id="sec23"><h3 class="pmc_sec_title">Neuroprotection</h3> <p>The potential neuroprotective actions of mifepristone have been demonstrated preclinically. Mifepristone was found to protect rat primary hippocampal neurons, clonal mouse hippocampal cells, and organotypic hippocampal slice cultures against oxidative stress-induced neuronal cell death induced by amyloid beta protein, hydrogen peroxide, and glutamate (<a href="#b3-ndt-2-33" class="usa-link" aria-describedby="b3-ndt-2-33">Behl et al 1997</a>). Interestingly, this effect was independent of the presence and activation of glucocorticoid or progesterone receptors. Other studies have also subsequently demonstrated neuroprotective effects of mifepristone (<a href="#b25-ndt-2-33" class="usa-link" aria-describedby="b25-ndt-2-33">Ghoumari et al 2003</a>), although the precise mechanism through which these actions are exerted is unclear. Nevertheless, these actions may be of therapeutic benefit.</p></section></section><section id="sec24"><h2 class="pmc_sec_title">Conclusions and future directions</h2> <p>The use of mifepristone and other GR antagonists in the treatment of mood disorders and psychosis is very much at the proof-of-concept stage. Results are encouraging and several larger-scale clinical trials are underway to better establish the clinical utility of this class of drug. Drugs targeting other facets of the HPA axis, such as CRH-1-receptor antagonists and vasopressin-1b-receptor antagonists, are also being examined (<a href="#b86-ndt-2-33" class="usa-link" aria-describedby="b86-ndt-2-33">Zobel et al 2000</a>; <a href="#b30-ndt-2-33" class="usa-link" aria-describedby="b30-ndt-2-33">Holmes et al 2003</a>; <a href="#b40-ndt-2-33" class="usa-link" aria-describedby="b40-ndt-2-33">Kunzel et al 2003</a>), as well as the application of GR antagonists in the treatment of mood symptoms and cognitive impairment in neurological disorders such as Alzheimer’s disease (<a href="#b62-ndt-2-33" class="usa-link" aria-describedby="b62-ndt-2-33">Pomara et al 2002</a>). Several important questions remain to be answered, including how long the treatment effects persist and the optimal method of administration, ie, continuous or repeated, short-term administrations. These data will provide valuable information on the overall efficacy and safety of this class of treatment (see <a href="#b46-ndt-2-33" class="usa-link" aria-describedby="b46-ndt-2-33">Mackin et al 2005</a>) and may ultimately lead to the development of specific antiglucocorticoid compounds for use in severe psychiatric illness.</p></section><section id="ref-list1" class="ref-list"><h2 class="pmc_sec_title">References</h2> <section id="ref-list1_sec2"><ol class="ref-list font-sm"> <li id="b1-ndt-2-33"> <cite>Ashok PW, Wagaarachchi PT, Templeton A. The antiprogestogen mifepristone: a review. Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents. 2002;2:71–90.</cite> [<a href="https://scholar.google.com/scholar_lookup?journal=Current%20Medicinal%20Chemistry%20-%20Immunology,%20Endocrine%20&%20Metabolic%20Agents&title=The%20antiprogestogen%20mifepristone:%20a%20review&author=PW%20Ashok&author=PT%20Wagaarachchi&author=A%20Templeton&volume=2&publication_year=2002&pages=71-90&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="b2-ndt-2-33"> <cite>Bachmann CG, Linthorst AC, Holsboer F, et al. Effect of chronic administration of selective glucocorticoid receptor antagonists on the rat hypothalamic-pituitary-adrenocortical axis. Neuropsychopharmacology. 2003;28:1056–67. doi: 10.1038/sj.npp.1300158.</cite> [<a href="https://doi.org/10.1038/sj.npp.1300158" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/12700716/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Neuropsychopharmacology&title=Effect%20of%20chronic%20administration%20of%20selective%20glucocorticoid%20receptor%20antagonists%20on%20the%20rat%20hypothalamic-pituitary-adrenocortical%20axis&author=CG%20Bachmann&author=AC%20Linthorst&author=F%20Holsboer&volume=28&publication_year=2003&pages=1056-67&pmid=12700716&doi=10.1038/sj.npp.1300158&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="b3-ndt-2-33"> <cite>Behl C, Trapp T, Skutella T, et al. Protection against oxidative stress-induced neuronal cell death – a novel role for RU486. Eur J Neurosci. 1997;9:912–20. doi: 10.1111/j.1460-9568.1997.tb01442.x.</cite> [<a href="https://doi.org/10.1111/j.1460-9568.1997.tb01442.x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/9182944/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Eur%20J%20Neurosci&title=Protection%20against%20oxidative%20stress-induced%20neuronal%20cell%20death%20%E2%80%93%20a%20novel%20role%20for%20RU486&author=C%20Behl&author=T%20Trapp&author=T%20Skutella&volume=9&publication_year=1997&pages=912-20&pmid=9182944&doi=10.1111/j.1460-9568.1997.tb01442.x&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="b4-ndt-2-33"> <cite>Belanoff JK, DeBattista C. Mifepristone in psychotic major depression. Biol Psychiatry. 2004;55(Suppl):191S. doi: 10.1016/s0006-3223(02)01432-4.</cite> [<a href="https://doi.org/10.1016/s0006-3223(02)01432-4" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/12242054/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Biol%20Psychiatry&title=Mifepristone%20in%20psychotic%20major%20depression&author=JK%20Belanoff&author=C%20DeBattista&volume=55&issue=Suppl&publication_year=2004&pages=191S&pmid=12242054&doi=10.1016/s0006-3223(02)01432-4&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="b5-ndt-2-33"> <cite>Belanoff JK, Flores BH, Kalezhan M, et al. Rapid reversal of psychotic depression using mifepristone. J Clin Psychopharmacol. 2001;21:516–21. doi: 10.1097/00004714-200110000-00009.</cite> [<a href="https://doi.org/10.1097/00004714-200110000-00009" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/11593077/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Clin%20Psychopharmacol&title=Rapid%20reversal%20of%20psychotic%20depression%20using%20mifepristone&author=JK%20Belanoff&author=BH%20Flores&author=M%20Kalezhan&volume=21&publication_year=2001&pages=516-21&pmid=11593077&doi=10.1097/00004714-200110000-00009&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="b6-ndt-2-33"> <cite>Belanoff JK, Rothschild AJ, Cassidy F, et al. An open label trial of C-1073 (mifepristone) for psychotic major depression. Biol Psychiatry. 2002;52:386–92. doi: 10.1016/s0006-3223(02)01432-4.</cite> [<a href="https://doi.org/10.1016/s0006-3223(02)01432-4" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/12242054/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Biol%20Psychiatry&title=An%20open%20label%20trial%20of%20C-1073%20(mifepristone)%20for%20psychotic%20major%20depression&author=JK%20Belanoff&author=AJ%20Rothschild&author=F%20Cassidy&volume=52&publication_year=2002&pages=386-92&pmid=12242054&doi=10.1016/s0006-3223(02)01432-4&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="b7-ndt-2-33"> <cite>Berne RM, Levy MN. Physiology. 4th ed. St Louis: Mosby Inc; 1998. </cite> [<a href="https://scholar.google.com/scholar_lookup?title=Physiology&author=RM%20Berne&author=MN%20Levy&publication_year=1998&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="b8-ndt-2-33"> <cite>Board F, Persky H, Hamburg DA. Psychological stress and endocrine functions; blood levels of adrenocortical and thyroid hormones in acutely disturbed patients. Psychosom Med. 1956;18:324–33. doi: 10.1097/00006842-195607000-00006.</cite> [<a href="https://doi.org/10.1097/00006842-195607000-00006" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/13350458/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Psychosom%20Med&title=Psychological%20stress%20and%20endocrine%20functions;%20blood%20levels%20of%20adrenocortical%20and%20thyroid%20hormones%20in%20acutely%20disturbed%20patients&author=F%20Board&author=H%20Persky&author=DA%20Hamburg&volume=18&publication_year=1956&pages=324-33&pmid=13350458&doi=10.1097/00006842-195607000-00006&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="b9-ndt-2-33"> <cite>Brouwer JP, Appelhof BC, Hoogendijk WJG, et al. Thyroid and adrenal axis in major depression: a controlled study in outpatients. Eur J Endocrinol. 2005;152:185–91. doi: 10.1530/eje.1.01828.</cite> [<a href="https://doi.org/10.1530/eje.1.01828" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/15745924/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Eur%20J%20Endocrinol&title=Thyroid%20and%20adrenal%20axis%20in%20major%20depression:%20a%20controlled%20study%20in%20outpatients&author=JP%20Brouwer&author=BC%20Appelhof&author=WJG%20Hoogendijk&volume=152&publication_year=2005&pages=185-91&pmid=15745924&doi=10.1530/eje.1.01828&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="b10-ndt-2-33"> <cite>Brown ES, Chandler PA. Mood and cognitive changes during systemic corticosteroid therapy. Prim Care Companion J Clin Psychiatry. 2001;3:17–21. doi: 10.4088/pcc.v03n0104.</cite> [<a href="https://doi.org/10.4088/pcc.v03n0104" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC181154/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/15014624/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Prim%20Care%20Companion%20J%20Clin%20Psychiatry&title=Mood%20and%20cognitive%20changes%20during%20systemic%20corticosteroid%20therapy&author=ES%20Brown&author=PA%20Chandler&volume=3&publication_year=2001&pages=17-21&pmid=15014624&doi=10.4088/pcc.v03n0104&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="b11-ndt-2-33"> <cite>Castro P, Lemaire M, Toscano-Aguilar M, et al. Abnormal DST results in patients with chronic schizophrenia. Am J Psychiatry. 1983;140:1261. doi: 10.1176/ajp.140.9.aj14091261.</cite> [<a href="https://doi.org/10.1176/ajp.140.9.aj14091261" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/6614251/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Am%20J%20Psychiatry&title=Abnormal%20DST%20results%20in%20patients%20with%20chronic%20schizophrenia&author=P%20Castro&author=M%20Lemaire&author=M%20Toscano-Aguilar&volume=140&publication_year=1983&pages=1261&pmid=6614251&doi=10.1176/ajp.140.9.aj14091261&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="b12-ndt-2-33"> <cite>Christie JE, Whalley LJ, Dick H, et al. Raised plasma cortisol concentrations a feature of drug-free psychotics and not specific for depression. Br J Psychiatry. 1986;148:58–65. doi: 10.1192/bjp.148.1.58.</cite> [<a href="https://doi.org/10.1192/bjp.148.1.58" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/3955320/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Br%20J%20Psychiatry&title=Raised%20plasma%20cortisol%20concentrations%20a%20feature%20of%20drug-free%20psychotics%20and%20not%20specific%20for%20depression&author=JE%20Christie&author=LJ%20Whalley&author=H%20Dick&volume=148&publication_year=1986&pages=58-65&pmid=3955320&doi=10.1192/bjp.148.1.58&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="b13-ndt-2-33"> <cite>Chu JW, Matthias DF, Belanoff J, et al. Successful long-term treatment of refractory Cushing’s disease with high-dose mifepristone (RU 486) J Clin Endocrinol Metab. 2001;86:3568–73. doi: 10.1210/jcem.86.8.7740.</cite> [<a href="https://doi.org/10.1210/jcem.86.8.7740" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/11502780/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Clin%20Endocrinol%20Metab&title=Successful%20long-term%20treatment%20of%20refractory%20Cushing%E2%80%99s%20disease%20with%20high-dose%20mifepristone%20(RU%20486)&author=JW%20Chu&author=DF%20Matthias&author=J%20Belanoff&volume=86&publication_year=2001&pages=3568-73&pmid=11502780&doi=10.1210/jcem.86.8.7740&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="b14-ndt-2-33"> <cite>de Kloet ER, Oitzl MS, Joels M. Stress and cognition: are corticosteroids good or bad guys? Trends Neurosci. 1999;22:422–6. doi: 10.1016/s0166-2236(99)01438-1.</cite> [<a href="https://doi.org/10.1016/s0166-2236(99)01438-1" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/10481183/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Trends%20Neurosci&title=Stress%20and%20cognition:%20are%20corticosteroids%20good%20or%20bad%20guys?&author=ER%20de%20Kloet&author=MS%20Oitzl&author=M%20Joels&volume=22&publication_year=1999&pages=422-6&pmid=10481183&doi=10.1016/s0166-2236(99)01438-1&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="b15-ndt-2-33"> <cite>DeBattista C, Belanoff J. A double-blind, placebo controlled trial of C-1073 (mifepristone) in the treatment of psychotic major depression. Neuropsychopharmacology. 2004;29(Suppl):S98.</cite> [<a href="https://scholar.google.com/scholar_lookup?journal=Neuropsychopharmacology&title=A%20double-blind,%20placebo%20controlled%20trial%20of%20C-1073%20(mifepristone)%20in%20the%20treatment%20of%20psychotic%20major%20depression&author=C%20DeBattista&author=J%20Belanoff&volume=29&issue=Suppl&publication_year=2004&pages=S98&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="b16-ndt-2-33"> <cite>Deuschle M, Schweiger U, Weber B, et al. Diurnal activity and pulsatility of the hypothalamus-pituitary-adrenal system in male depressed patients and healthy controls. J Clin Endocrinol Metab. 1997;82:234–8. doi: 10.1210/jcem.82.1.3689.</cite> [<a href="https://doi.org/10.1210/jcem.82.1.3689" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/8989265/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Clin%20Endocrinol%20Metab&title=Diurnal%20activity%20and%20pulsatility%20of%20the%20hypothalamus-pituitary-adrenal%20system%20in%20male%20depressed%20patients%20and%20healthy%20controls&author=M%20Deuschle&author=U%20Schweiger&author=B%20Weber&volume=82&publication_year=1997&pages=234-8&pmid=8989265&doi=10.1210/jcem.82.1.3689&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="b17-ndt-2-33"> <cite>Dorn LD, Burgess ES, Friedman TC, et al. The longitudinal course of psychopathology in Cushing’s syndrome after correction of hypercortisolism. J Clin Endocrinol Metab. 1997;82:912–9. doi: 10.1210/jcem.82.3.3834.</cite> [<a href="https://doi.org/10.1210/jcem.82.3.3834" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/9062506/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Clin%20Endocrinol%20Metab&title=The%20longitudinal%20course%20of%20psychopathology%20in%20Cushing%E2%80%99s%20syndrome%20after%20correction%20of%20hypercortisolism&author=LD%20Dorn&author=ES%20Burgess&author=TC%20Friedman&volume=82&publication_year=1997&pages=912-9&pmid=9062506&doi=10.1210/jcem.82.3.3834&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="b18-ndt-2-33"> <cite>Duval F, Mokrani MC, Crocq MA, et al. Dopaminergic function and the cortisol response to dexamethasone in psychotic depression. Prog Neuropsychopharmacol Biol Psychiatry. 2000;24:207–25. doi: 10.1016/s0278-5846(99)00098-6.</cite> [<a href="https://doi.org/10.1016/s0278-5846(99)00098-6" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/10800744/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Prog%20Neuropsychopharmacol%20Biol%20Psychiatry&title=Dopaminergic%20function%20and%20the%20cortisol%20response%20to%20dexamethasone%20in%20psychotic%20depression&author=F%20Duval&author=MC%20Mokrani&author=MA%20Crocq&volume=24&publication_year=2000&pages=207-25&pmid=10800744&doi=10.1016/s0278-5846(99)00098-6&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="b19-ndt-2-33"> <cite>Elvevag B, Goldberg TE. Cognitive impairment in schizophrenia is the core of the disorder. Crit Rev Neurobiol. 2000;14:1–21.</cite> [<a href="https://pubmed.ncbi.nlm.nih.gov/11253953/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Crit%20Rev%20Neurobiol&title=Cognitive%20impairment%20in%20schizophrenia%20is%20the%20core%20of%20the%20disorder&author=B%20Elvevag&author=TE%20Goldberg&volume=14&publication_year=2000&pages=1-21&pmid=11253953&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="b20-ndt-2-33"> <cite>First MB, Spitzer RL, Williams JBW, et al. Structured clinical interview for DSM-IV (SCID-I), research version. New York: Biometrics Research Department, New York State Psychiatric Institute; 1995. </cite> [<a href="https://scholar.google.com/scholar_lookup?title=Structured%20clinical%20interview%20for%20DSM-IV%20(SCID-I),%20research%20version&author=MB%20First&author=RL%20Spitzer&author=JBW%20Williams&publication_year=1995&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="b21-ndt-2-33"> <cite>Fleming SK, Blasey C, Schatzberg AF. Neuropsychological correlates of psychotic features in major depressive disorders: a review and meta-analysis. J Psychiatr Res. 2004;38:27–35. doi: 10.1016/s0022-3956(03)00100-6.</cite> [<a href="https://doi.org/10.1016/s0022-3956(03)00100-6" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/14690768/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Psychiatr%20Res&title=Neuropsychological%20correlates%20of%20psychotic%20features%20in%20major%20depressive%20disorders:%20a%20review%20and%20meta-analysis&author=SK%20Fleming&author=C%20Blasey&author=AF%20Schatzberg&volume=38&publication_year=2004&pages=27-35&pmid=14690768&doi=10.1016/s0022-3956(03)00100-6&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="b22-ndt-2-33"> <cite>Foldesi I, Falkay G, Kovacs L. Determination of RU486 (mifepristone) in blood by radioreceptorassay; a pharmacokinetic study. Contraception. 1996;54:27–32. doi: 10.1016/0010-7824(96)00116-3.</cite> [<a href="https://doi.org/10.1016/0010-7824(96)00116-3" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/8804805/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Contraception&title=Determination%20of%20RU486%20(mifepristone)%20in%20blood%20by%20radioreceptorassay;%20a%20pharmacokinetic%20study&author=I%20Foldesi&author=G%20Falkay&author=L%20Kovacs&volume=54&publication_year=1996&pages=27-32&pmid=8804805&doi=10.1016/0010-7824(96)00116-3&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="b23-ndt-2-33"> <cite>Forget H, Lacroix A, Cohen H. Persistent cognitive impairment following surgical treatment of Cushing’s syndrome. Psychoneuroendocrinology. 2002;27:367–83. doi: 10.1016/s0306-4530(01)00059-2.</cite> [<a href="https://doi.org/10.1016/s0306-4530(01)00059-2" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/11818172/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Psychoneuroendocrinology&title=Persistent%20cognitive%20impairment%20following%20surgical%20treatment%20of%20Cushing%E2%80%99s%20syndrome&author=H%20Forget&author=A%20Lacroix&author=H%20Cohen&volume=27&publication_year=2002&pages=367-83&pmid=11818172&doi=10.1016/s0306-4530(01)00059-2&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="b24-ndt-2-33"> <cite>Gallagher P, Watson S, Smith MS, et al. Effects of adjunctive mifepristone (RU-486) administration on neurocognitive function and symptoms in schizophrenia. Biol Psychiatry. 2005;57:155–61. doi: 10.1016/j.biopsych.2004.10.017.</cite> [<a href="https://doi.org/10.1016/j.biopsych.2004.10.017" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/15652874/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Biol%20Psychiatry&title=Effects%20of%20adjunctive%20mifepristone%20(RU-486)%20administration%20on%20neurocognitive%20function%20and%20symptoms%20in%20schizophrenia&author=P%20Gallagher&author=S%20Watson&author=MS%20Smith&volume=57&publication_year=2005&pages=155-61&pmid=15652874&doi=10.1016/j.biopsych.2004.10.017&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="b25-ndt-2-33"> <cite>Ghoumari AM, Dusart I, El-Etr M, et al. Mifepristone (RU486) protects Purkinje cells from cell death in organotypic slice cultures of postnatal rat and mouse cerebellum. Proc Natl Acad Sci U S A. 2003;100:7953–8. doi: 10.1073/pnas.1332667100.</cite> [<a href="https://doi.org/10.1073/pnas.1332667100" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC164694/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/12810951/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Proc%20Natl%20Acad%20Sci%20U%20S%20A&title=Mifepristone%20(RU486)%20protects%20Purkinje%20cells%20from%20cell%20death%20in%20organotypic%20slice%20cultures%20of%20postnatal%20rat%20and%20mouse%20cerebellum&author=AM%20Ghoumari&author=I%20Dusart&author=M%20El-Etr&volume=100&publication_year=2003&pages=7953-8&pmid=12810951&doi=10.1073/pnas.1332667100&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="b26-ndt-2-33"> <cite>Gibbons JL. Cortisol secretion rate in depressive illness. Arch Gen Psychiatry. 1964;10:572–5. doi: 10.1001/archpsyc.1964.01720240026004.</cite> [<a href="https://doi.org/10.1001/archpsyc.1964.01720240026004" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/14159257/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Arch%20Gen%20Psychiatry&title=Cortisol%20secretion%20rate%20in%20depressive%20illness&author=JL%20Gibbons&volume=10&publication_year=1964&pages=572-5&pmid=14159257&doi=10.1001/archpsyc.1964.01720240026004&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="b27-ndt-2-33"> <cite>Grunberg SM, Weiss MH, Spitz IM, et al. Treatment of unresectable meningiomas with the antiprogesterone agent mifepristone. J Neurosurg. 1991;74:861–6. doi: 10.3171/jns.1991.74.6.0861.</cite> [<a href="https://doi.org/10.3171/jns.1991.74.6.0861" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/2033444/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Neurosurg&title=Treatment%20of%20unresectable%20meningiomas%20with%20the%20antiprogesterone%20agent%20mifepristone&author=SM%20Grunberg&author=MH%20Weiss&author=IM%20Spitz&volume=74&publication_year=1991&pages=861-6&pmid=2033444&doi=10.3171/jns.1991.74.6.0861&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="b28-ndt-2-33"> <cite>Hazra BG, Pore VS. Mifepristone (RU-486), the recently developed antiprogesterone drug and its analogues. J Indian Inst Sci. 2001;81:287–98.</cite> [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Indian%20Inst%20Sci&title=Mifepristone%20(RU-486),%20the%20recently%20developed%20antiprogesterone%20drug%20and%20its%20analogues&author=BG%20Hazra&author=VS%20Pore&volume=81&publication_year=2001&pages=287-98&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="b29-ndt-2-33"> <cite>Herrmann W, Wyss R, Riondel A, et al. The effects of an antiprogesterone steroid in women: interruption of the menstrual cycle and of early pregnancy. C R Seances Acad Sci III. 1982;294:933–8.</cite> [<a href="https://pubmed.ncbi.nlm.nih.gov/6814714/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=C%20R%20Seances%20Acad%20Sci%20III&title=The%20effects%20of%20an%20antiprogesterone%20steroid%20in%20women:%20interruption%20of%20the%20menstrual%20cycle%20and%20of%20early%20pregnancy&author=W%20Herrmann&author=R%20Wyss&author=A%20Riondel&volume=294&publication_year=1982&pages=933-8&pmid=6814714&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="b30-ndt-2-33"> <cite>Holmes A, Heilig M, Rupniak NMJ, et al. Neuropeptide systems as novel therapeutic targets for depression and anxiety disorders. Trends Pharmacol Sci. 2003;24:580–8. doi: 10.1016/j.tips.2003.09.011.</cite> [<a href="https://doi.org/10.1016/j.tips.2003.09.011" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/14607081/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Trends%20Pharmacol%20Sci&title=Neuropeptide%20systems%20as%20novel%20therapeutic%20targets%20for%20depression%20and%20anxiety%20disorders&author=A%20Holmes&author=M%20Heilig&author=NMJ%20Rupniak&volume=24&publication_year=2003&pages=580-8&pmid=14607081&doi=10.1016/j.tips.2003.09.011&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="b31-ndt-2-33"> <cite>Høyberg ØJ, Wik G, Mehtonen OP, et al. ORG 34517, a selective glucocorticoid receptor antagonist with potent antidepressant activity: First clinical results. Int J Neuropsychopharmacol. 2002;5:S148.</cite> [<a href="https://scholar.google.com/scholar_lookup?journal=Int%20J%20Neuropsychopharmacol&title=ORG%2034517,%20a%20selective%20glucocorticoid%20receptor%20antagonist%20with%20potent%20antidepressant%20activity:%20First%20clinical%20results&author=%C3%98J%20H%C3%B8yberg&author=G%20Wik&author=OP%20Mehtonen&volume=5&publication_year=2002&pages=S148&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="b32-ndt-2-33"> <cite>Ismail K, Murray RM, Wheeler MJ, et al. The dexamethasone suppression test in schizophrenia. Psychol Med. 1998;28:311–17. doi: 10.1017/s0033291797006521.</cite> [<a href="https://doi.org/10.1017/s0033291797006521" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/9572089/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Psychol%20Med&title=The%20dexamethasone%20suppression%20test%20in%20schizophrenia&author=K%20Ismail&author=RM%20Murray&author=MJ%20Wheeler&volume=28&publication_year=1998&pages=311-17&pmid=9572089&doi=10.1017/s0033291797006521&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="b33-ndt-2-33"> <cite>Jahn H, Schick M, Kiefer F, et al. Metyrapone as additive treatment in major depression: a double-blind and placebo-controlled trial. Arch Gen Psychiatry. 2004;61:1235–44. doi: 10.1001/archpsyc.61.12.1235.</cite> [<a href="https://doi.org/10.1001/archpsyc.61.12.1235" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/15583115/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Arch%20Gen%20Psychiatry&title=Metyrapone%20as%20additive%20treatment%20in%20major%20depression:%20a%20double-blind%20and%20placebo-controlled%20trial&author=H%20Jahn&author=M%20Schick&author=F%20Kiefer&volume=61&publication_year=2004&pages=1235-44&pmid=15583115&doi=10.1001/archpsyc.61.12.1235&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="b34-ndt-2-33"> <cite>Jung-Testas I, Baulieu EE. Inhibition of glucocorticosteroid action in cultured L-929 mouse fibroblasts by RU 486, a new anti-glucocorticosteroid of high affinity for the glucocorticosteroid receptor. Exp Cell Res. 1983;147:177–82. doi: 10.1016/0014-4827(83)90282-3.</cite> [<a href="https://doi.org/10.1016/0014-4827(83)90282-3" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/6617759/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Exp%20Cell%20Res&title=Inhibition%20of%20glucocorticosteroid%20action%20in%20cultured%20L-929%20mouse%20fibroblasts%20by%20RU%20486,%20a%20new%20anti-glucocorticosteroid%20of%20high%20affinity%20for%20the%20glucocorticosteroid%20receptor&author=I%20Jung-Testas&author=EE%20Baulieu&volume=147&publication_year=1983&pages=177-82&pmid=6617759&doi=10.1016/0014-4827(83)90282-3&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="b35-ndt-2-33"> <cite>Kessels RP, de Haan EH, Kappelle LJ, et al. Varieties of human spatial memory: a meta-analysis on the effects of hippocampal lesions. Brain Res Brain Res Rev. 2001;35:295–303. doi: 10.1016/s0165-0173(01)00058-3.</cite> [<a href="https://doi.org/10.1016/s0165-0173(01)00058-3" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/11423159/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Brain%20Res%20Brain%20Res%20Rev&title=Varieties%20of%20human%20spatial%20memory:%20a%20meta-analysis%20on%20the%20effects%20of%20hippocampal%20lesions&author=RP%20Kessels&author=EH%20de%20Haan&author=LJ%20Kappelle&volume=35&publication_year=2001&pages=295-303&pmid=11423159&doi=10.1016/s0165-0173(01)00058-3&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="b36-ndt-2-33"> <cite>Kessels RP, Postma A, Wijnalda EM, et al. Frontal-lobe involvement in spatial memory: evidence from PET, fMRI, and lesion studies. Neuropsychol Rev. 2000;10:101–13. doi: 10.1023/a:1009016820717.</cite> [<a href="https://doi.org/10.1023/a:1009016820717" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/10937918/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Neuropsychol%20Rev&title=Frontal-lobe%20involvement%20in%20spatial%20memory:%20evidence%20from%20PET,%20fMRI,%20and%20lesion%20studies&author=RP%20Kessels&author=A%20Postma&author=EM%20Wijnalda&volume=10&publication_year=2000&pages=101-13&pmid=10937918&doi=10.1023/a:1009016820717&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="b37-ndt-2-33"> <cite>Kling MA, Whitfield HJJ, Brandt HA, et al. Effects of glucocorticoid antagonism with RU 486 on pituitary-adrenal function in patients with major depression: time-dependent enhancement of plasma ACTH secretion. Psychopharmacol Bull. 1989;25:466–72.</cite> [<a href="https://pubmed.ncbi.nlm.nih.gov/2560555/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Psychopharmacol%20Bull&title=Effects%20of%20glucocorticoid%20antagonism%20with%20RU%20486%20on%20pituitary-adrenal%20function%20in%20patients%20with%20major%20depression:%20time-dependent%20enhancement%20of%20plasma%20ACTH%20secretion&author=MA%20Kling&author=HJJ%20Whitfield&author=HA%20Brandt&volume=25&publication_year=1989&pages=466-72&pmid=2560555&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="b38-ndt-2-33"> <cite>Knable MB, Torrey EF, Webster MJ, et al. Multivariate analysis of prefrontal cortical data from the Stanley Foundation Neuropathology Consortium. Brain Res Bull. 2001;55:651–9. doi: 10.1016/s0361-9230(01)00521-4.</cite> [<a href="https://doi.org/10.1016/s0361-9230(01)00521-4" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/11576762/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Brain%20Res%20Bull&title=Multivariate%20analysis%20of%20prefrontal%20cortical%20data%20from%20the%20Stanley%20Foundation%20Neuropathology%20Consortium&author=MB%20Knable&author=EF%20Torrey&author=MJ%20Webster&volume=55&publication_year=2001&pages=651-9&pmid=11576762&doi=10.1016/s0361-9230(01)00521-4&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="b39-ndt-2-33"> <cite>Krishnan KR, Reed D, Wilson WH, et al. RU486 in depression. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 1992;16:913–20. doi: 10.1016/0278-5846(92)90109-r.</cite> [<a href="https://doi.org/10.1016/0278-5846(92)90109-r" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/1325068/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Progress%20in%20Neuro-Psychopharmacology%20&%20Biological%20Psychiatry&title=RU486%20in%20depression&author=KR%20Krishnan&author=D%20Reed&author=WH%20Wilson&volume=16&publication_year=1992&pages=913-20&pmid=1325068&doi=10.1016/0278-5846(92)90109-r&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="b40-ndt-2-33"> <cite>Kunzel HE, Zobel AW, Nickel T, et al. Treatment of depression with the CRH-1-receptor antagonist R121919: endocrine changes and side effects. J Psychiatr Res. 2003;37:525–33. doi: 10.1016/s0022-3956(03)00070-0.</cite> [<a href="https://doi.org/10.1016/s0022-3956(03)00070-0" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/14563384/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Psychiatr%20Res&title=Treatment%20of%20depression%20with%20the%20CRH-1-receptor%20antagonist%20R121919:%20endocrine%20changes%20and%20side%20effects&author=HE%20Kunzel&author=AW%20Zobel&author=T%20Nickel&volume=37&publication_year=2003&pages=525-33&pmid=14563384&doi=10.1016/s0022-3956(03)00070-0&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="b41-ndt-2-33"> <cite>Lahteenmaki P, Heikinheimo O, Croxatto H, et al. Pharmacokinetics and metabolism of RU 486. J Steroid Biochem. 1987;27:859–63. doi: 10.1016/0022-4731(87)90160-9.</cite> [<a href="https://doi.org/10.1016/0022-4731(87)90160-9" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/3695508/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Steroid%20Biochem&title=Pharmacokinetics%20and%20metabolism%20of%20RU%20486&author=P%20Lahteenmaki&author=O%20Heikinheimo&author=H%20Croxatto&volume=27&publication_year=1987&pages=859-63&pmid=3695508&doi=10.1016/0022-4731(87)90160-9&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="b42-ndt-2-33"> <cite>Laue L, Lotze MT, Chrousos GP, et al. Effect of chronic treatment with the glucocorticoid antagonist RU 486 in man: toxicity, immunological, and hormonal aspects. J Clin Endocrinol Metab. 1990;71:1474–80. doi: 10.1210/jcem-71-6-1474.</cite> [<a href="https://doi.org/10.1210/jcem-71-6-1474" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/2172280/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Clin%20Endocrinol%20Metab&title=Effect%20of%20chronic%20treatment%20with%20the%20glucocorticoid%20antagonist%20RU%20486%20in%20man:%20toxicity,%20immunological,%20and%20hormonal%20aspects&author=L%20Laue&author=MT%20Lotze&author=GP%20Chrousos&volume=71&publication_year=1990&pages=1474-80&pmid=2172280&doi=10.1210/jcem-71-6-1474&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="b43-ndt-2-33"> <cite>Leminen R, Ranta S, von Hertzen H, et al. Pharmacokinetics of 10 mg of mifepristone. Contraception. 2003;68:427–9. doi: 10.1016/s0010-7824(03)00181-1.</cite> [<a href="https://doi.org/10.1016/s0010-7824(03)00181-1" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/14698072/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Contraception&title=Pharmacokinetics%20of%2010%20mg%20of%20mifepristone&author=R%20Leminen&author=S%20Ranta&author=H%20von%20Hertzen&volume=68&publication_year=2003&pages=427-9&pmid=14698072&doi=10.1016/s0010-7824(03)00181-1&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="b44-ndt-2-33"> <cite>Lopez JF, Little KY, Lopez-Figueroa AL, et al. Glucocorticoid and mineralocorticoid receptor mRNA levels in the hippocampus and prefrontal cortex of subjects with mood disorders and schizophrenia. Biol Psychiatry. 2003;53:489.</cite> [<a href="https://scholar.google.com/scholar_lookup?journal=Biol%20Psychiatry&title=Glucocorticoid%20and%20mineralocorticoid%20receptor%20mRNA%20levels%20in%20the%20hippocampus%20and%20prefrontal%20cortex%20of%20subjects%20with%20mood%20disorders%20and%20schizophrenia&author=JF%20Lopez&author=KY%20Little&author=AL%20Lopez-Figueroa&volume=53&publication_year=2003&pages=489&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="b45-ndt-2-33"> <cite>Lupien SJ, McEwen BS. The acute effects of corticosteroids on cognition: integration of animal and human model studies. Brain Res Brain Res Rev. 1997;24:1–27. doi: 10.1016/s0165-0173(97)00004-0.</cite> [<a href="https://doi.org/10.1016/s0165-0173(97)00004-0" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/9233540/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Brain%20Res%20Brain%20Res%20Rev&title=The%20acute%20effects%20of%20corticosteroids%20on%20cognition:%20integration%20of%20animal%20and%20human%20model%20studies&author=SJ%20Lupien&author=BS%20McEwen&volume=24&publication_year=1997&pages=1-27&pmid=9233540&doi=10.1016/s0165-0173(97)00004-0&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="b46-ndt-2-33"> <cite>Mackin P, Gallagher P, Froom K, et al. Antiglucocorticoid treatments in mood disorders: efficacy and safety. (Protocol) The Cochrane Database Syst Rev. 2005:1. doi: 10.1002/14651858.CD005168. [online]. Art nr CD005168. URL: <a href="http://www.thecochranelibrary.com" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">http://www.thecochranelibrary.com</a>.</cite> [<a href="https://doi.org/10.1002/14651858.CD005168" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>]</li> <li id="b47-ndt-2-33"> <cite>McAllister-Williams RH, Ferrier IN, Young AH. Mood and neuropsychological function in depression: the role of corticosteroids and serotonin. Psychol Med. 1998;28:573–84. doi: 10.1017/s0033291798006680.</cite> [<a href="https://doi.org/10.1017/s0033291798006680" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/9626714/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Psychol%20Med&title=Mood%20and%20neuropsychological%20function%20in%20depression:%20the%20role%20of%20corticosteroids%20and%20serotonin&author=RH%20McAllister-Williams&author=IN%20Ferrier&author=AH%20Young&volume=28&publication_year=1998&pages=573-84&pmid=9626714&doi=10.1017/s0033291798006680&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="b48-ndt-2-33"> <cite>McQuade R, Young AH. Future therapeutic targets in mood disorders: the glucocorticoid receptor. Br J Psychiatry. 2000;177:390–5. doi: 10.1192/bjp.177.5.390.</cite> [<a href="https://doi.org/10.1192/bjp.177.5.390" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/11059990/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Br%20J%20Psychiatry&title=Future%20therapeutic%20targets%20in%20mood%20disorders:%20the%20glucocorticoid%20receptor&author=R%20McQuade&author=AH%20Young&volume=177&publication_year=2000&pages=390-5&pmid=11059990&doi=10.1192/bjp.177.5.390&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="b49-ndt-2-33"> <cite>Modell S, Yassouridis A, Huber J, et al. Corticosteroid receptor function is decreased in depressed patients. Neuroendocrinology. 1997;65:216–22. doi: 10.1159/000127275.</cite> [<a href="https://doi.org/10.1159/000127275" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/9088003/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Neuroendocrinology&title=Corticosteroid%20receptor%20function%20is%20decreased%20in%20depressed%20patients&author=S%20Modell&author=A%20Yassouridis&author=J%20Huber&volume=65&publication_year=1997&pages=216-22&pmid=9088003&doi=10.1159/000127275&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="b50-ndt-2-33"> <cite>Muck-Seler D, Pivac N, Jakovljevic M, et al. Platelet serotonin, plasma cortisol, and dexamethasone suppression test in schizophrenic patients. Biol Psychiatry. 1999;45:1433–9. doi: 10.1016/s0006-3223(98)00174-7.</cite> [<a href="https://doi.org/10.1016/s0006-3223(98)00174-7" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/10356625/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Biol%20Psychiatry&title=Platelet%20serotonin,%20plasma%20cortisol,%20and%20dexamethasone%20suppression%20test%20in%20schizophrenic%20patients&author=D%20Muck-Seler&author=N%20Pivac&author=M%20Jakovljevic&volume=45&publication_year=1999&pages=1433-9&pmid=10356625&doi=10.1016/s0006-3223(98)00174-7&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="b51-ndt-2-33"> <cite>Murphy BEP, Filipini D, Ghadirian AM. Possible uses of glucocorticoid receptor antagonists in the treatment of major depression: Preliminary results using RU-486. J Psychiatry Neurosci. 1993;18:209–13.</cite> [<a href="/articles/PMC1188541/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/8297920/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Psychiatry%20Neurosci&title=Possible%20uses%20of%20glucocorticoid%20receptor%20antagonists%20in%20the%20treatment%20of%20major%20depression:%20Preliminary%20results%20using%20RU-486&author=BEP%20Murphy&author=D%20Filipini&author=AM%20Ghadirian&volume=18&publication_year=1993&pages=209-13&pmid=8297920&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="b52-ndt-2-33"> <cite>Nieman LK, Chrousos GP, Kellner C, et al. Successful treatment of Cushing’s syndrome with the glucocorticoid antagonist RU 486. J Clin Endocrinol Metab. 1985;61:536–40. doi: 10.1210/jcem-61-3-536.</cite> [<a href="https://doi.org/10.1210/jcem-61-3-536" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/2991327/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Clin%20Endocrinol%20Metab&title=Successful%20treatment%20of%20Cushing%E2%80%99s%20syndrome%20with%20the%20glucocorticoid%20antagonist%20RU%20486&author=LK%20Nieman&author=GP%20Chrousos&author=C%20Kellner&volume=61&publication_year=1985&pages=536-40&pmid=2991327&doi=10.1210/jcem-61-3-536&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="b53-ndt-2-33"> <cite>Oitzl MS, Fluttert M, de Kloet ER. Acute blockade of hippocampal glucocorticoid receptors facilitates spatial learning in rats. Brain Res. 1998a;797:159–62. doi: 10.1016/s0006-8993(98)00387-4.</cite> [<a href="https://doi.org/10.1016/s0006-8993(98)00387-4" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/9630598/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Brain%20Res&title=Acute%20blockade%20of%20hippocampal%20glucocorticoid%20receptors%20facilitates%20spatial%20learning%20in%20rats&author=MS%20Oitzl&author=M%20Fluttert&author=ER%20de%20Kloet&volume=797&publication_year=1998a&pages=159-62&pmid=9630598&doi=10.1016/s0006-8993(98)00387-4&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="b54-ndt-2-33"> <cite>Oitzl MS, Fluttert M, Sutanto W, et al. Continuous blockade of brain glucocorticoid receptors facilitates spatial learning and memory in rats. Eur J Neurosci. 1998b;10:3759–66. doi: 10.1046/j.1460-9568.1998.00381.x.</cite> [<a href="https://doi.org/10.1046/j.1460-9568.1998.00381.x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/9875354/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Eur%20J%20Neurosci&title=Continuous%20blockade%20of%20brain%20glucocorticoid%20receptors%20facilitates%20spatial%20learning%20and%20memory%20in%20rats&author=MS%20Oitzl&author=M%20Fluttert&author=W%20Sutanto&volume=10&publication_year=1998b&pages=3759-66&pmid=9875354&doi=10.1046/j.1460-9568.1998.00381.x&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="b55-ndt-2-33"> <cite>Owen AM, Morris RG, Sahakian BJ, et al. Double dissociations of memory and executive functions in working memory tasks following frontal lobe excisions, temporal lobe excisions or amygdalo-hippocampectomy in man. Brain. 1996;119:1597–615. doi: 10.1093/brain/119.5.1597.</cite> [<a href="https://doi.org/10.1093/brain/119.5.1597" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/8931583/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Brain&title=Double%20dissociations%20of%20memory%20and%20executive%20functions%20in%20working%20memory%20tasks%20following%20frontal%20lobe%20excisions,%20temporal%20lobe%20excisions%20or%20amygdalo-hippocampectomy%20in%20man&author=AM%20Owen&author=RG%20Morris&author=BJ%20Sahakian&volume=119&publication_year=1996&pages=1597-615&pmid=8931583&doi=10.1093/brain/119.5.1597&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="b56-ndt-2-33"> <cite>Owen AM, Sahakian BJ, Semple J, et al. Visuo-spatial short-term recognition memory and learning after temporal lobe excisions, frontal lobe excisions or amygdalo-hippocampectomy in man. Neuropsychologia. 1995;33:1–24. doi: 10.1016/0028-3932(94)00098-a.</cite> [<a href="https://doi.org/10.1016/0028-3932(94)00098-a" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/7731533/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Neuropsychologia&title=Visuo-spatial%20short-term%20recognition%20memory%20and%20learning%20after%20temporal%20lobe%20excisions,%20frontal%20lobe%20excisions%20or%20amygdalo-hippocampectomy%20in%20man&author=AM%20Owen&author=BJ%20Sahakian&author=J%20Semple&volume=33&publication_year=1995&pages=1-24&pmid=7731533&doi=10.1016/0028-3932(94)00098-a&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="b57-ndt-2-33"> <cite>Pariante CM. Depression, Stress and the Adrenal axis. J Neuroendocrinol. 2003;15:811–12. doi: 10.1046/j.1365-2826.2003.01058.x.</cite> [<a href="https://doi.org/10.1046/j.1365-2826.2003.01058.x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/12834443/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Neuroendocrinol&title=Depression,%20Stress%20and%20the%20Adrenal%20axis&author=CM%20Pariante&volume=15&publication_year=2003&pages=811-12&pmid=12834443&doi=10.1046/j.1365-2826.2003.01058.x&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="b58-ndt-2-33"> <cite>Pariante CM. Glucocorticoid receptor function in vitro in patients with major depression. Stress. 2004;7:209–19. doi: 10.1080/10253890500069650.</cite> [<a href="https://doi.org/10.1080/10253890500069650" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/16019586/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Stress&title=Glucocorticoid%20receptor%20function%20in%20vitro%20in%20patients%20with%20major%20depression&author=CM%20Pariante&volume=7&publication_year=2004&pages=209-19&pmid=16019586&doi=10.1080/10253890500069650&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="b59-ndt-2-33"> <cite>Pariante CM, Thomas SA, Lovestone S, et al. Do antidepressants regulate how cortisol affects the brain? Psychoneuroendocrinology. 2004a;29:423–47. doi: 10.1016/j.psyneuen.2003.10.009.</cite> [<a href="https://doi.org/10.1016/j.psyneuen.2003.10.009" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/14749091/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Psychoneuroendocrinology&title=Do%20antidepressants%20regulate%20how%20cortisol%20affects%20the%20brain?&author=CM%20Pariante&author=SA%20Thomas&author=S%20Lovestone&volume=29&publication_year=2004a&pages=423-47&pmid=14749091&doi=10.1016/j.psyneuen.2003.10.009&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="b60-ndt-2-33"> <cite>Pariante CM, Vassilopoulou K, Velakoulis D, et al. Pituitary volume in psychosis. Br J Psychiatry. 2004b;185:5–10. doi: 10.1192/bjp.185.1.5.</cite> [<a href="https://doi.org/10.1192/bjp.185.1.5" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/15231549/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Br%20J%20Psychiatry&title=Pituitary%20volume%20in%20psychosis&author=CM%20Pariante&author=K%20Vassilopoulou&author=D%20Velakoulis&volume=185&publication_year=2004b&pages=5-10&pmid=15231549&doi=10.1192/bjp.185.1.5&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="b61-ndt-2-33"> <cite>Patel PD, Lopez JF, Lyons DM, et al. Glucocorticoid and mineralocorticoid receptor mRNA expression in squirrel monkey brain. J Psychiatr Res. 2000;34:383–92. doi: 10.1016/s0022-3956(00)00035-2.</cite> [<a href="https://doi.org/10.1016/s0022-3956(00)00035-2" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/11165305/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Psychiatr%20Res&title=Glucocorticoid%20and%20mineralocorticoid%20receptor%20mRNA%20expression%20in%20squirrel%20monkey%20brain&author=PD%20Patel&author=JF%20Lopez&author=DM%20Lyons&volume=34&publication_year=2000&pages=383-92&pmid=11165305&doi=10.1016/s0022-3956(00)00035-2&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="b62-ndt-2-33"> <cite>Pomara N, Doraiswamy PM, Tun H, et al. Mifepristone (RU 486) for Alzheimer’s disease. Neurology. 2002;58:1436–7. doi: 10.1212/wnl.58.9.1436.</cite> [<a href="https://doi.org/10.1212/wnl.58.9.1436" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/12011303/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Neurology&title=Mifepristone%20(RU%20486)%20for%20Alzheimer%E2%80%99s%20disease&author=N%20Pomara&author=PM%20Doraiswamy&author=H%20Tun&volume=58&publication_year=2002&pages=1436-7&pmid=12011303&doi=10.1212/wnl.58.9.1436&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="b63-ndt-2-33"> <cite>Porter RJ, Gallagher P, Thompson JM, et al. Neurocognitive impairment in drug-free patients with major depressive disorder. Br J Psychiatry. 2003;182:214–20. doi: 10.1192/bjp.182.3.214.</cite> [<a href="https://doi.org/10.1192/bjp.182.3.214" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/12611784/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Br%20J%20Psychiatry&title=Neurocognitive%20impairment%20in%20drug-free%20patients%20with%20major%20depressive%20disorder&author=RJ%20Porter&author=P%20Gallagher&author=JM%20Thompson&volume=182&publication_year=2003&pages=214-20&pmid=12611784&doi=10.1192/bjp.182.3.214&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="b64-ndt-2-33"> <cite>Porter RJ, Gallagher P, Watson S, et al. Corticosteroid-serotonin interactions in depression: a review of the human evidence. Psychopharmacology (Berl) 2004;173:1–17. doi: 10.1007/s00213-004-1774-1.</cite> [<a href="https://doi.org/10.1007/s00213-004-1774-1" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/15007595/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Psychopharmacology%20(Berl)&title=Corticosteroid-serotonin%20interactions%20in%20depression:%20a%20review%20of%20the%20human%20evidence&author=RJ%20Porter&author=P%20Gallagher&author=S%20Watson&volume=173&publication_year=2004&pages=1-17&pmid=15007595&doi=10.1007/s00213-004-1774-1&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="b65-ndt-2-33"> <cite>Posener JA, DeBattista C, Williams GH, et al. 24-hour monitoring of cortisol and corticotropin secretion in psychotic and nonpsychotic major depression. Arch Gen Psychiatry. 2000;57:755–60. doi: 10.1001/archpsyc.57.8.755.</cite> [<a href="https://doi.org/10.1001/archpsyc.57.8.755" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/10920463/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Arch%20Gen%20Psychiatry&title=24-hour%20monitoring%20of%20cortisol%20and%20corticotropin%20secretion%20in%20psychotic%20and%20nonpsychotic%20major%20depression&author=JA%20Posener&author=C%20DeBattista&author=GH%20Williams&volume=57&publication_year=2000&pages=755-60&pmid=10920463&doi=10.1001/archpsyc.57.8.755&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="b66-ndt-2-33"> <cite>Reul JM, de Kloet ER. Two receptor systems for corticosterone in rat brain: microdistribution and differential occupation. Endocrinology. 1985;117:2505–11. doi: 10.1210/endo-117-6-2505.</cite> [<a href="https://doi.org/10.1210/endo-117-6-2505" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/2998738/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Endocrinology&title=Two%20receptor%20systems%20for%20corticosterone%20in%20rat%20brain:%20microdistribution%20and%20differential%20occupation&author=JM%20Reul&author=ER%20de%20Kloet&volume=117&publication_year=1985&pages=2505-11&pmid=2998738&doi=10.1210/endo-117-6-2505&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="b67-ndt-2-33"> <cite>Ritsner M, Maayan R, Gibel A, et al. Elevation of the cortisol/ dehydroepiandrosterone ratio in schizophrenia patients. Eur Neuropsychopharmacol. 2004;14:267–73. doi: 10.1016/j.euroneuro.2003.09.003.</cite> [<a href="https://doi.org/10.1016/j.euroneuro.2003.09.003" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/15163435/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Eur%20Neuropsychopharmacol&title=Elevation%20of%20the%20cortisol/%20dehydroepiandrosterone%20ratio%20in%20schizophrenia%20patients&author=M%20Ritsner&author=R%20Maayan&author=A%20Gibel&volume=14&publication_year=2004&pages=267-73&pmid=15163435&doi=10.1016/j.euroneuro.2003.09.003&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="b68-ndt-2-33"> <cite>Rush AJ, Giles DE, Schlesser MA, et al. The dexamethasone suppression test in patients with mood disorders. J Clin Psychiatry. 1996;57:470–84. doi: 10.4088/jcp.v57n1006.</cite> [<a href="https://doi.org/10.4088/jcp.v57n1006" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/8909334/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Clin%20Psychiatry&title=The%20dexamethasone%20suppression%20test%20in%20patients%20with%20mood%20disorders&author=AJ%20Rush&author=DE%20Giles&author=MA%20Schlesser&volume=57&publication_year=1996&pages=470-84&pmid=8909334&doi=10.4088/jcp.v57n1006&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="b69-ndt-2-33"> <cite>Ryan MC, Sharifi N, Condren R, et al. Evidence of basal pituitary-adrenal overactivity in first episode, drug naive patients with schizophrenia. Psychoneuroendocrinology. 2004;29:1065–70. doi: 10.1016/j.psyneuen.2003.08.011.</cite> [<a href="https://doi.org/10.1016/j.psyneuen.2003.08.011" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/15219658/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Psychoneuroendocrinology&title=Evidence%20of%20basal%20pituitary-adrenal%20overactivity%20in%20first%20episode,%20drug%20naive%20patients%20with%20schizophrenia&author=MC%20Ryan&author=N%20Sharifi&author=R%20Condren&volume=29&publication_year=2004&pages=1065-70&pmid=15219658&doi=10.1016/j.psyneuen.2003.08.011&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="b70-ndt-2-33"> <cite>Rybakowski JK, Twardowska K. The dexamethasone/corticotropin-releasing hormone test in depression in bipolar and unipolar affective illness. J Psychiatr Res. 1999;33:363–70. doi: 10.1016/s0022-3956(99)00014-x.</cite> [<a href="https://doi.org/10.1016/s0022-3956(99)00014-x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/10504004/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Psychiatr%20Res&title=The%20dexamethasone/corticotropin-releasing%20hormone%20test%20in%20depression%20in%20bipolar%20and%20unipolar%20affective%20illness&author=JK%20Rybakowski&author=K%20Twardowska&volume=33&publication_year=1999&pages=363-70&pmid=10504004&doi=10.1016/s0022-3956(99)00014-x&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="b71-ndt-2-33"> <cite>Sartor O, Cutler GB., Jr Mifepristone: treatment of Cushing’s syndrome. Clin Obstet Gynecol. 1996;39:506–10. doi: 10.1097/00003081-199606000-00024.</cite> [<a href="https://doi.org/10.1097/00003081-199606000-00024" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/8734015/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin%20Obstet%20Gynecol&title=Mifepristone:%20treatment%20of%20Cushing%E2%80%99s%20syndrome&author=O%20Sartor&author=GB%20Cutler&volume=39&publication_year=1996&pages=506-10&pmid=8734015&doi=10.1097/00003081-199606000-00024&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="b72-ndt-2-33"> <cite>Schmider J, Lammers CH, Gotthardt U, et al. Combined dexamethasone/corticotropin-releasing hormone test in acute and remitted manic patients, in acute depression, and in normal controls: I. Biol Psychiatry. 1995;38:797–802. doi: 10.1016/0006-3223(95)00064-X.</cite> [<a href="https://doi.org/10.1016/0006-3223(95)00064-X" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/8750037/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Biol%20Psychiatry&title=Combined%20dexamethasone/corticotropin-releasing%20hormone%20test%20in%20acute%20and%20remitted%20manic%20patients,%20in%20acute%20depression,%20and%20in%20normal%20controls:%20I&author=J%20Schmider&author=CH%20Lammers&author=U%20Gotthardt&volume=38&publication_year=1995&pages=797-802&pmid=8750037&doi=10.1016/0006-3223(95)00064-X&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="b73-ndt-2-33"> <cite>Simpson GM, El Sheshai A, Loza N, et al. An 8-week open-label trial of a 6-day course of mifepristone for the treatment of psychotic depression. J Clin Psychiatry. 2005;66:598–602. doi: 10.4088/jcp.v66n0509.</cite> [<a href="https://doi.org/10.4088/jcp.v66n0509" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/15889946/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Clin%20Psychiatry&title=An%208-week%20open-label%20trial%20of%20a%206-day%20course%20of%20mifepristone%20for%20the%20treatment%20of%20psychotic%20depression&author=GM%20Simpson&author=A%20El%20Sheshai&author=N%20Loza&volume=66&publication_year=2005&pages=598-602&pmid=15889946&doi=10.4088/jcp.v66n0509&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="b74-ndt-2-33"> <cite>Sitruk-Ware R, Spitz IM. Pharmacological properties of mifepristone: toxicology and safety in animal and human studies. Contraception. 2003;68:409–20. doi: 10.1016/s0010-7824(03)00171-9.</cite> [<a href="https://doi.org/10.1016/s0010-7824(03)00171-9" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/14698070/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Contraception&title=Pharmacological%20properties%20of%20mifepristone:%20toxicology%20and%20safety%20in%20animal%20and%20human%20studies&author=R%20Sitruk-Ware&author=IM%20Spitz&volume=68&publication_year=2003&pages=409-20&pmid=14698070&doi=10.1016/s0010-7824(03)00171-9&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="b75-ndt-2-33"> <cite>Spitz IM, Bardin CW. Clinical pharmacology of RU 486–an antiprogestin and antiglucocorticoid. Contraception. 1993;48:403–44. doi: 10.1016/0010-7824(93)90133-r.</cite> [<a href="https://doi.org/10.1016/0010-7824(93)90133-r" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/8275693/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Contraception&title=Clinical%20pharmacology%20of%20RU%20486%E2%80%93an%20antiprogestin%20and%20antiglucocorticoid&author=IM%20Spitz&author=CW%20Bardin&volume=48&publication_year=1993&pages=403-44&pmid=8275693&doi=10.1016/0010-7824(93)90133-r&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="b76-ndt-2-33"> <cite>Starkman MN, Giordani B, Berent S, et al. Elevated cortisol levels in Cushing’s disease are associated with cognitive decrements. Psychosom Med. 2001;63:985–93. doi: 10.1097/00006842-200111000-00018.</cite> [<a href="https://doi.org/10.1097/00006842-200111000-00018" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/11719638/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Psychosom%20Med&title=Elevated%20cortisol%20levels%20in%20Cushing%E2%80%99s%20disease%20are%20associated%20with%20cognitive%20decrements&author=MN%20Starkman&author=B%20Giordani&author=S%20Berent&volume=63&publication_year=2001&pages=985-93&pmid=11719638&doi=10.1097/00006842-200111000-00018&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="b77-ndt-2-33"> <cite>Strickland PL, Deakin JF, Percival C, et al. Bio-social origins of depression in the community. Interactions between social adversity, cortisol and serotonin neurotransmission. Br J Psychiatry. 2002;180:168–73. doi: 10.1192/bjp.180.2.168.</cite> [<a href="https://doi.org/10.1192/bjp.180.2.168" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/11823330/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Br%20J%20Psychiatry&title=Bio-social%20origins%20of%20depression%20in%20the%20community.%20Interactions%20between%20social%20adversity,%20cortisol%20and%20serotonin%20neurotransmission&author=PL%20Strickland&author=JF%20Deakin&author=C%20Percival&volume=180&publication_year=2002&pages=168-73&pmid=11823330&doi=10.1192/bjp.180.2.168&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="b78-ndt-2-33"> <cite>Thompson JM, Gallagher P, Hughes JH, et al. Neurocognitive impairment in euthymic bipolar disorder. Br J Psychiatry. 2005;186:32–40. doi: 10.1192/bjp.186.1.32.</cite> [<a href="https://doi.org/10.1192/bjp.186.1.32" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/15630121/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Br%20J%20Psychiatry&title=Neurocognitive%20impairment%20in%20euthymic%20bipolar%20disorder&author=JM%20Thompson&author=P%20Gallagher&author=JH%20Hughes&volume=186&publication_year=2005&pages=32-40&pmid=15630121&doi=10.1192/bjp.186.1.32&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="b79-ndt-2-33"> <cite>van der Lely AJ, Foeken K, van der Mast RC, et al. Rapid reversal of acute psychosis in the Cushing syndrome with the cortisol-receptor antagonist mifepristone (RU 486) Ann Intern Med. 1991;114:143–4. doi: 10.7326/0003-4819-114-2-143.</cite> [<a href="https://doi.org/10.7326/0003-4819-114-2-143" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/1984391/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Ann%20Intern%20Med&title=Rapid%20reversal%20of%20acute%20psychosis%20in%20the%20Cushing%20syndrome%20with%20the%20cortisol-receptor%20antagonist%20mifepristone%20(RU%20486)&author=AJ%20van%20der%20Lely&author=K%20Foeken&author=RC%20van%20der%20Mast&volume=114&publication_year=1991&pages=143-4&pmid=1984391&doi=10.7326/0003-4819-114-2-143&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="b80-ndt-2-33"> <cite>Watson S, Gallagher P, Ritchie JC, et al. Hypothalamic-pituitary-adrenal axis function in patients with bipolar disorder. Br J Psychiatry. 2004;184:496–502. doi: 10.1192/bjp.184.6.496.</cite> [<a href="https://doi.org/10.1192/bjp.184.6.496" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/15172943/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Br%20J%20Psychiatry&title=Hypothalamic-pituitary-adrenal%20axis%20function%20in%20patients%20with%20bipolar%20disorder&author=S%20Watson&author=P%20Gallagher&author=JC%20Ritchie&volume=184&publication_year=2004&pages=496-502&pmid=15172943&doi=10.1192/bjp.184.6.496&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="b81-ndt-2-33"> <cite>Webster MJ, Knable MB, O’Grady J, et al. Regional specificity of brain glucocorticoid receptor mRNA alterations in subjects with schizophrenia and mood disorders. Mol Psychiatry. 2002;7:985–94. doi: 10.1038/sj.mp.4001139.</cite> [<a href="https://doi.org/10.1038/sj.mp.4001139" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/12399952/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Mol%20Psychiatry&title=Regional%20specificity%20of%20brain%20glucocorticoid%20receptor%20mRNA%20alterations%20in%20subjects%20with%20schizophrenia%20and%20mood%20disorders&author=MJ%20Webster&author=MB%20Knable&author=J%20O%E2%80%99Grady&volume=7&publication_year=2002&pages=985-94&pmid=12399952&doi=10.1038/sj.mp.4001139&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="b82-ndt-2-33"> <cite>Young AH, Gallagher P, Porter RJ. Elevation of the cortisol-dehydroepiandrosterone ratio in drug-free depressed patients. Am J Psychiatry. 2002;159:1237–9. doi: 10.1176/appi.ajp.159.7.1237.</cite> [<a href="https://doi.org/10.1176/appi.ajp.159.7.1237" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/12091208/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Am%20J%20Psychiatry&title=Elevation%20of%20the%20cortisol-dehydroepiandrosterone%20ratio%20in%20drug-free%20depressed%20patients&author=AH%20Young&author=P%20Gallagher&author=RJ%20Porter&volume=159&publication_year=2002&pages=1237-9&pmid=12091208&doi=10.1176/appi.ajp.159.7.1237&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="b83-ndt-2-33"> <cite>Young AH, Gallagher P, Watson S, et al. Improvements in neurocognitive function and mood following adjunctive treatment with mifepristone (RU-486) in bipolar disorder. Neuropsychopharmacology. 2004;29:1538–45. doi: 10.1038/sj.npp.1300471.</cite> [<a href="https://doi.org/10.1038/sj.npp.1300471" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/15127079/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Neuropsychopharmacology&title=Improvements%20in%20neurocognitive%20function%20and%20mood%20following%20adjunctive%20treatment%20with%20mifepristone%20(RU-486)%20in%20bipolar%20disorder&author=AH%20Young&author=P%20Gallagher&author=S%20Watson&volume=29&publication_year=2004&pages=1538-45&pmid=15127079&doi=10.1038/sj.npp.1300471&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="b84-ndt-2-33"> <cite>Young AH, Sahakian BJ, Robbins TW, et al. The effects of chronic administration of hydrocortisone on cognitive function in normal male volunteers. Psychopharmacology (Berl) 1999;145:260–6. doi: 10.1007/s002130051057.</cite> [<a href="https://doi.org/10.1007/s002130051057" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/10494574/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Psychopharmacology%20(Berl)&title=The%20effects%20of%20chronic%20administration%20of%20hydrocortisone%20on%20cognitive%20function%20in%20normal%20male%20volunteers&author=AH%20Young&author=BJ%20Sahakian&author=TW%20Robbins&volume=145&publication_year=1999&pages=260-6&pmid=10494574&doi=10.1007/s002130051057&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="b85-ndt-2-33"> <cite>Young EA, Lopez JF, Murphy-Weinberg V, et al. Mineralocorticoid receptor function in major depression. Arch Gen Psychiatry. 2003;60:24–8. doi: 10.1001/archpsyc.60.1.24.</cite> [<a href="https://doi.org/10.1001/archpsyc.60.1.24" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/12511169/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Arch%20Gen%20Psychiatry&title=Mineralocorticoid%20receptor%20function%20in%20major%20depression&author=EA%20Young&author=JF%20Lopez&author=V%20Murphy-Weinberg&volume=60&publication_year=2003&pages=24-8&pmid=12511169&doi=10.1001/archpsyc.60.1.24&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> <li id="b86-ndt-2-33"> <cite>Zobel AW, Nickel T, Kunzel HE, et al. Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated. J Psychiatr Res. 2000;34:171–81. doi: 10.1016/s0022-3956(00)00016-9.</cite> [<a href="https://doi.org/10.1016/s0022-3956(00)00016-9" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/10867111/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Psychiatr%20Res&title=Effects%20of%20the%20high-affinity%20corticotropin-releasing%20hormone%20receptor%201%20antagonist%20R121919%20in%20major%20depression:%20the%20first%2020%20patients%20treated&author=AW%20Zobel&author=T%20Nickel&author=HE%20Kunzel&volume=34&publication_year=2000&pages=171-81&pmid=10867111&doi=10.1016/s0022-3956(00)00016-9&" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li> </ol></section></section></section><footer class="p courtesy-note font-secondary font-sm text-center"><hr class="headless"> <p>Articles from Neuropsychiatric Disease and Treatment are provided here courtesy of <strong>Dove Press</strong></p></footer></section></article> </main> </div> </div> </div>  <div class="pmc-sidenav desktop:grid-col-4 display-flex"> <section class="pmc-sidenav__container" aria-label="Article resources and navigation"> <button type="button" class="usa-button pmc-sidenav__container__close usa-button--unstyled"> <img src="/static/img/usa-icons/close.svg" role="img" alt="Close" /> </button> <div class="display-none desktop:display-block"> <section class="margin-top-4 desktop:margin-top-0"> <h2 class="margin-top-0">ACTIONS</h2> <ul class="usa-list usa-list--unstyled usa-list--actions"> <li> <a href="pdf/ndt-2-33.pdf" class="usa-button usa-button--outline width-24 display-inline-flex flex-align-center flex-justify-start padding-left-1" data-ga-category="actions" data-ga-action="click" data-ga-label="pdf_download_desktop" > <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden> <use xlink:href="/static/img/sprite.svg#file_download"></use> </svg> <span class="display-inline-flex flex-justify-center flex-1">PDF (91.2 KB)</span> </a> </li> <li> <button role="button" class="usa-button width-24 citation-dialog-trigger display-inline-flex flex-align-center flex-justify-start padding-left-1" aria-label="Open dialog with citation text in different styles" data-ga-category="actions" data-ga-action="open" data-ga-label="cite_desktop" data-all-citations-url="/resources/citations/2671735/" data-citation-style="nlm" data-download-format-link="/resources/citations/2671735/export/" > <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden> <use xlink:href="/static/img/sprite.svg#format_quote"></use> </svg> <span class="display-inline-flex flex-justify-center flex-1 button-label">Cite</span> </button> </li> <li> <button class="usa-button width-24 collections-dialog-trigger collections-button display-inline-flex flex-align-center flex-justify-start padding-left-1 collections-button-empty" aria-label="Save article in MyNCBI collections." data-ga-category="actions" data-ga-action="click" data-ga-label="collections_button_desktop" data-collections-open-dialog-enabled="false" data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC2671735%2F%23open-collections-dialog" data-in-collections="false"> <svg class="usa-icon width-3 height-3 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden> <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use> </svg> <svg class="usa-icon width-3 height-3 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden> <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use> </svg> <span class="display-inline-flex flex-justify-center flex-1">Collections</span> </button> </li> <li class="pmc-permalink"> <button type="button" class="usa-button width-24 display-inline-flex flex-align-center flex-justify padding-left-1 shadow-none" aria-label="Show article permalink" aria-expanded="false" aria-haspopup="true" data-ga-category="actions" data-ga-action="open" data-ga-label="permalink_desktop" > <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden> <use xlink:href="/static/img/sprite.svg#share"></use> </svg> <span class="display-inline-flex flex-justify-center flex-1 button-label">Permalink</span> </button> <div class="pmc-permalink__dropdown" hidden> <div class="pmc-permalink__dropdown__container"> <h2 class="usa-modal__heading margin-top-0 margin-bottom-2">PERMALINK</h2> <div class="pmc-permalink__dropdown__content"> <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC2671735/" aria-label="Article permalink"> <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link"> <svg class="usa-icon" aria-hidden="true" focusable="false" role="img"> <use xlink:href="/static/img/sprite.svg#content_copy"></use> </svg> <span class="margin-left-1">Copy</span> </button> </div> </div> </div> </li> </ul> </section> </div> <section class="pmc-resources margin-top-6 desktop:margin-top-4" data-page-path="/articles/PMC2671735/"> <h2 class="margin-top-0">RESOURCES</h2> <div class="usa-accordion usa-accordion--multiselectable" data-allow-multiple> <h3 class="usa-accordion__heading"> <button type="button" class="usa-accordion__button" aria-expanded="false" aria-controls="resources-similar-articles" data-ga-category="resources_accordion" data-ga-action="open_similar_articles" data-ga-label="/articles/PMC2671735/" data-action-open="open_similar_articles" data-action-close="close_similar_articles" > Similar articles </button> </h3> <div id="resources-similar-articles" class="usa-accordion__content usa-prose" data-source-url="/resources/similar-article-links/19412444/" > </div> <h3 class="usa-accordion__heading"> <button type="button" class="usa-accordion__button" aria-expanded="false" aria-controls="resources-cited-by-other-articles" data-ga-category="resources_accordion" data-ga-action="open_cited_by" data-ga-label="/articles/PMC2671735/" data-action-open="open_cited_by" data-action-close="close_cited_by" > Cited by other articles </button> </h3> <div id="resources-cited-by-other-articles" class="usa-accordion__content usa-prose" data-source-url="/resources/cited-by-links/19412444/" > </div> <h3 class="usa-accordion__heading"> <button type="button" class="usa-accordion__button" aria-expanded="false" aria-controls="resources-links-to-ncbi-databases" data-ga-category="resources_accordion" data-ga-action="open_NCBI_links" data-ga-label="/articles/PMC2671735/" data-action-open="open_NCBI_links" data-action-close="close_NCBI_link" > Links to NCBI Databases </button> </h3> <div id="resources-links-to-ncbi-databases" class="usa-accordion__content usa-prose" data-source-url="/resources/db-links/2671735/" > </div> </div> </section> <section class="usa-in-page-nav usa-in-page-nav--wide margin-top-6 desktop:margin-top-4" data-title-text="On this page" data-title-heading-level="h2" data-scroll-offset="0" data-root-margin="-10% 0px -80% 0px" data-main-content-selector="main" data-threshold="1" hidden ></section> </section> </div> <div class="overlay" role="dialog" aria-label="Citation Dialog" hidden> <div class="dialog citation-dialog" aria-hidden="true"> <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2"> <h2 class="usa-modal__heading margin-0">Cite</h2> <button type="button" class="usa-button usa-button--unstyled close-overlay text-black width-auto" tabindex="1"> <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img"> <use xlink:href="/static/img/sprite.svg#close"></use> </svg> </button> </div> <div class="citation-text-block"> <div class="citation-text margin-bottom-2"></div> <ul class="usa-list usa-list--unstyled display-inline-flex flex-justify width-full flex-align-center"> <li> <button class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center copy-button dialog-focus" data-ga-category="save_share" data-ga-action="cite" data-ga-label="copy" tabindex="2"> <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img"> <use xlink:href="/static/img/sprite.svg#content_copy"></use> </svg> <span>Copy</span> </button> </li> <li> <a href="#" role="button" class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center export-button" data-ga-category="save_share" data-ga-action="cite" data-ga-label="download" title="Download a file for external citation management software" tabindex="3"> <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img"> <use xlink:href="/static/img/sprite.svg#file_download"></use> </svg> <span class="display-none mobile-lg:display-inline">Download .nbib</span> <span class="display-inline mobile-lg:display-none">.nbib</span> </a> </li> <li> <div class="display-inline-flex flex-align-center"> <label class="usa-label margin-top-0">Format:</label> <select aria-label="Format" class="usa-select citation-style-selector padding-1 margin-top-0 border-0 padding-right-4" tabindex="4" > <option data-style-url-name="ama" value="AMA" > AMA </option> <option data-style-url-name="apa" value="APA" > APA </option> <option data-style-url-name="mla" value="MLA" > MLA </option> <option data-style-url-name="nlm" value="NLM" selected="selected"> NLM </option> </select> </div> </li> </ul> </div> </div> </div> <div class="overlay" role="dialog" hidden> <div id="collections-action-dialog" class="dialog collections-dialog" aria-hidden="true"> <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2"> <h2 class="usa-modal__heading margin-0">Add to Collections</h2> </div> <div class="collections-action-panel action-panel"> <form id="collections-action-dialog-form" class="usa-form maxw-full collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors" data-existing-collections-url="/list-existing-collections/" data-add-to-existing-collection-url="/add-to-existing-collection/" data-create-and-add-to-new-collection-url="/create-and-add-to-new-collection/" data-myncbi-max-collection-name-length="100" data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/"> <input type="hidden" name="csrfmiddlewaretoken" value="9wWCHKC0prWL2aObSbpqbtzc3U9rukRgHpPbFqOAS5CuN2Ep0fUMUJcYEHkgfRaM"> <fieldset class="usa-fieldset margin-bottom-2"> <div class="usa-radio"> <input type="radio" id="collections-action-dialog-new" class="usa-radio__input usa-radio__input--tile collections-new margin-top-0" name="collections" value="new" data-ga-category="collections_button" data-ga-action="click" data-ga-label="collections_radio_new" /> <label class="usa-radio__label" for="collections-action-dialog-new">Create a new collection</label> </div> <div class="usa-radio"> <input type="radio" id="collections-action-dialog-existing" class="usa-radio__input usa-radio__input--tile collections-existing" name="collections" value="existing" checked="true" data-ga-category="collections_button" data-ga-action="click" data-ga-label="collections_radio_existing" /> <label class="usa-radio__label" for="collections-action-dialog-existing">Add to an existing collection</label> </div> </fieldset> <fieldset class="usa-fieldset margin-bottom-2"> <div class="action-panel-control-wrap new-collections-controls"> <label for="collections-action-dialog-add-to-new" class="usa-label margin-top-0"> Name your collection <abbr title="required" class="usa-hint usa-hint--required text-no-underline">*</abbr> </label> <input type="text" name="add-to-new-collection" id="collections-action-dialog-add-to-new" class="usa-input collections-action-add-to-new" pattern="[^"&=<>/]*" title="The following characters are not allowed in the Name field: "&=<>/" maxlength="" data-ga-category="collections_button" data-ga-action="create_collection" data-ga-label="non_favorties_collection" required /> </div> <div class="action-panel-control-wrap existing-collections-controls"> <label for="collections-action-dialog-add-to-existing" class="usa-label margin-top-0"> Choose a collection </label> <select id="collections-action-dialog-add-to-existing" class="usa-select collections-action-add-to-existing" data-ga-category="collections_button" data-ga-action="select_collection" data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'"> </select> <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message"> Unable to load your collection due to an error<br> <a href="#">Please try again</a> </div> </div> </fieldset> <div class="display-inline-flex"> <button class="usa-button margin-top-0 action-panel-submit" type="submit" data-loading-label="Adding..." data-pinger-ignore data-ga-category="collections_button" data-ga-action="click" data-ga-label="add"> Add </button> <button class="usa-button usa-button--outline margin-top-0 action-panel-cancel" aria-label="Close 'Add to Collections' panel" ref="linksrc=close_collections_panel" data-ga-category="collections_button" data-ga-action="click" data-ga-label="cancel"> Cancel </button> </div> </form> </div> </div> </div> </div> </div> </div> <footer class="ncbi-footer ncbi-dark-background " > <div class="ncbi-footer__icon-section"> <div class="ncbi-footer__social-header"> Follow NCBI </div> <div class="grid-container ncbi-footer__ncbi-social-icons-container"> <a href="https://twitter.com/ncbi" class="ncbi-footer__social-icon ncbi-footer__social-icon--gray" target="_blank" rel="noreferrer noopener"> <svg width="40" height="40" viewBox="0 0 40 40" fill="none" xmlns="http://www.w3.org/2000/svg" focusable="false" aria-hidden="true"> <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z"> </path> </svg> <span class="usa-sr-only">NCBI on X (formerly known as Twitter)</span> </a> <a href="https://www.facebook.com/ncbi.nlm" class="ncbi-footer__social-icon ncbi-footer__social-icon--gray" target="_blank" rel="noreferrer noopener"> <svg width="16" height="29" focusable="false" aria-hidden="true" viewBox="0 0 16 29" fill="none" xmlns="http://www.w3.org/2000/svg"> <path d="M3.8809 21.4002C3.8809 19.0932 3.8809 16.7876 3.8809 14.478C3.8809 14.2117 3.80103 14.1452 3.54278 14.1492C2.53372 14.1638 1.52334 14.1492 0.514288 14.1598C0.302626 14.1598 0.248047 14.0972 0.248047 13.8936C0.256034 12.4585 0.256034 11.0239 0.248047 9.58978C0.248047 9.37013 0.302626 9.30224 0.528931 9.3049C1.53798 9.31688 2.54837 9.3049 3.55742 9.31555C3.80103 9.31555 3.8809 9.26097 3.87957 9.00272C3.87158 8.00565 3.85428 7.00592 3.90753 6.00884C3.97142 4.83339 4.31487 3.73115 5.04437 2.78467C5.93095 1.63318 7.15699 1.09005 8.56141 0.967577C10.5582 0.79319 12.555 0.982221 14.5518 0.927641C14.7102 0.927641 14.7462 0.99287 14.7449 1.13664C14.7449 2.581 14.7449 4.02668 14.7449 5.47104C14.7449 5.67604 14.6517 5.68669 14.4946 5.68669C13.4523 5.68669 12.4113 5.68669 11.3703 5.68669C10.3506 5.68669 9.92057 6.10868 9.90593 7.13904C9.89661 7.7647 9.91525 8.39303 9.89794 9.01869C9.88995 9.26364 9.96583 9.31822 10.2015 9.31688C11.7204 9.30623 13.2393 9.31688 14.7595 9.3049C15.0257 9.3049 15.0723 9.3728 15.0444 9.62439C14.89 10.9849 14.7515 12.3467 14.6144 13.7085C14.5691 14.1571 14.5785 14.1585 14.1458 14.1585C12.8386 14.1585 11.5313 14.1665 10.2254 14.1518C9.95119 14.1518 9.89794 14.2317 9.89794 14.4899C9.90593 19.0799 9.89794 23.6752 9.91125 28.2612C9.91125 28.5674 9.8407 28.646 9.53186 28.6433C7.77866 28.6273 6.02414 28.6366 4.27094 28.634C3.82499 28.634 3.87158 28.6992 3.87158 28.22C3.87602 25.9472 3.87913 23.6739 3.8809 21.4002Z"> </path> </svg> <span class="usa-sr-only">NCBI on Facebook</span> </a> <a href="https://www.linkedin.com/company/ncbinlm" class="ncbi-footer__social-icon ncbi-footer__social-icon--gray" target="_blank" rel="noreferrer noopener"> <svg width="25" height="23" viewBox="0 0 26 24" fill="none" xmlns="http://www.w3.org/2000/svg" focusable="false" aria-hidden="true"> <path d="M14.6983 9.98423C15.6302 9.24808 16.5926 8.74754 17.6762 8.51991C19.673 8.09126 21.554 8.30824 23.1262 9.7526C24.2351 10.7723 24.7529 12.1115 25.0165 13.5612C25.1486 14.3363 25.2105 15.1218 25.2015 15.9081C25.2015 18.3043 25.2015 20.6898 25.2082 23.0806C25.2082 23.3468 25.1549 23.444 24.8621 23.4414C23.1297 23.4272 21.3992 23.4272 19.6704 23.4414C19.4041 23.4414 19.3429 23.3588 19.3442 23.1019C19.3535 20.5194 19.3442 17.9368 19.3442 15.3543C19.3442 14.0005 18.3258 12.9448 17.0266 12.9488C15.7273 12.9528 14.6983 14.0071 14.6983 15.361C14.6983 17.9328 14.6917 20.5047 14.6983 23.0753C14.6983 23.3708 14.6198 23.444 14.3296 23.4427C12.6185 23.4294 10.9079 23.4294 9.19779 23.4427C8.93155 23.4427 8.86099 23.3735 8.86232 23.1086C8.8783 19.7619 8.88628 16.4144 8.88628 13.066C8.88628 11.5688 8.87874 10.0708 8.86365 8.57182C8.86365 8.3575 8.90758 8.27896 9.14054 8.28029C10.9048 8.29094 12.6687 8.29094 14.4321 8.28029C14.6464 8.28029 14.6983 8.34818 14.6983 8.54653C14.6903 9.00047 14.6983 9.45441 14.6983 9.98423Z"> </path> <path d="M6.55316 15.8443C6.55316 18.2564 6.55316 20.6699 6.55316 23.082C6.55316 23.3629 6.48127 23.4388 6.19906 23.4374C4.47737 23.4241 2.75568 23.4241 1.03399 23.4374C0.767751 23.4374 0.69986 23.3629 0.701191 23.1006C0.709178 18.2648 0.709178 13.4281 0.701191 8.59053C0.701191 8.34026 0.765089 8.27237 1.01669 8.2737C2.74991 8.28435 4.48048 8.28435 6.20838 8.2737C6.47462 8.2737 6.5465 8.33627 6.54517 8.6065C6.54783 11.0186 6.55316 13.4308 6.55316 15.8443Z"> </path> <path d="M3.65878 0.243898C5.36804 0.243898 6.58743 1.45529 6.58743 3.1406C6.58743 4.75801 5.32145 5.95742 3.60819 5.96807C3.22177 5.97614 2.83768 5.90639 2.47877 5.76299C2.11985 5.61959 1.79344 5.40546 1.51897 5.13334C1.24449 4.86123 1.02755 4.53668 0.881058 4.17902C0.734563 3.82136 0.661505 3.43788 0.666231 3.05141C0.67555 1.42601 1.9362 0.242566 3.65878 0.243898Z"> </path> </svg> <span class="usa-sr-only">NCBI on LinkedIn</span> </a> <a href="https://github.com/ncbi" class="ncbi-footer__social-icon ncbi-footer__social-icon--gray" target="_blank" rel="noreferrer noopener"> <svg width="28" height="27" viewBox="0 0 28 28" fill="none" xmlns="http://www.w3.org/2000/svg" focusable="false" aria-hidden="true"> <path d="M16.7228 20.6334C17.5057 20.5527 18.2786 20.3944 19.0301 20.1608C21.3108 19.4193 22.5822 17.8259 22.963 15.4909C23.1228 14.5112 23.1814 13.5287 22.9883 12.5437C22.8106 11.6423 22.4013 10.8028 21.8007 10.1076C21.7526 10.0605 21.7197 10 21.7064 9.934C21.6931 9.86799 21.7 9.79952 21.7262 9.73748C22.0856 8.6206 21.9711 7.51969 21.601 6.42677C21.582 6.3497 21.5345 6.2827 21.468 6.23923C21.4016 6.19577 21.3211 6.17906 21.2429 6.19248C20.7329 6.21649 20.2313 6.33051 19.7611 6.52928C19.1103 6.7908 18.4899 7.12198 17.9104 7.51703C17.84 7.56996 17.7581 7.60551 17.6713 7.62078C17.5846 7.63605 17.4954 7.6306 17.4112 7.60489C15.2596 7.05882 13.0054 7.06203 10.8554 7.61421C10.7806 7.63586 10.7018 7.63967 10.6253 7.62534C10.5487 7.611 10.4766 7.57892 10.4148 7.53167C9.64788 7.03247 8.85171 6.58918 7.96368 6.33359C7.65781 6.24338 7.34123 6.19458 7.02239 6.18849C6.94879 6.17986 6.87462 6.19893 6.81432 6.242C6.75402 6.28507 6.71191 6.34904 6.69621 6.42145C6.32342 7.51437 6.2209 8.61527 6.56307 9.73348C6.59635 9.84264 6.64694 9.93316 6.54177 10.0516C5.47666 11.2604 5.09988 12.6834 5.19574 14.2676C5.2663 15.4244 5.46201 16.5466 6.01454 17.5769C6.84399 19.1171 8.21664 19.9119 9.85158 20.3352C10.3938 20.4706 10.9444 20.5698 11.4998 20.632C11.5384 20.7492 11.4506 20.7798 11.408 20.8291C11.1734 21.1179 10.9894 21.4441 10.8634 21.7942C10.7622 22.0458 10.8315 22.4039 10.6065 22.5516C10.263 22.7766 9.83827 22.8485 9.42421 22.8871C8.17936 23.0056 7.26471 22.4877 6.6283 21.4348C6.25552 20.8184 5.76956 20.3325 5.08523 20.0663C4.76981 19.9325 4.42139 19.8967 4.08537 19.9638C3.7898 20.029 3.73788 20.1901 3.93891 20.4111C4.03639 20.5234 4.14989 20.6207 4.27575 20.6999C4.9796 21.1318 5.51717 21.7884 5.80152 22.5636C6.37002 23.9973 7.48039 24.5697 8.93825 24.6323C9.43741 24.6575 9.93768 24.615 10.4254 24.5058C10.5892 24.4672 10.6531 24.4872 10.6517 24.6762C10.6451 25.4936 10.6637 26.3123 10.6517 27.131C10.6517 27.6635 10.1684 27.9297 9.58663 27.7393C8.17396 27.2671 6.84977 26.5631 5.66838 25.656C2.59555 23.2891 0.720966 20.1861 0.217704 16.3376C-0.357453 11.9127 0.911353 8.00824 3.98551 4.73881C6.11909 2.42656 8.99932 0.939975 12.1203 0.540191C16.5351 -0.0601815 20.4347 1.14323 23.7232 4.16373C26.2449 6.47869 27.724 9.37672 28.1048 12.7726C28.5828 17.0325 27.3686 20.7945 24.4768 23.9827C22.9762 25.6323 21.0956 26.8908 18.9982 27.6488C18.8783 27.6927 18.7585 27.738 18.636 27.7726C18.0356 27.9404 17.6189 27.6395 17.6189 27.0098C17.6189 25.7452 17.6308 24.4806 17.6295 23.2159C17.6329 22.9506 17.6128 22.6856 17.5696 22.4238C17.4325 21.6664 17.3419 21.484 16.7228 20.6334Z"> </path> </svg> <span class="usa-sr-only">NCBI on GitHub</span> </a> <a href="https://ncbiinsights.ncbi.nlm.nih.gov/" class="ncbi-footer__social-icon ncbi-footer__social-icon--gray" target="_blank" rel="noreferrer noopener"> <svg width="26" height="26" viewBox="0 0 27 27" fill="none" xmlns="http://www.w3.org/2000/svg" focusable="false" aria-hidden="true"> <path d="M23.7778 26.4574C23.1354 26.3913 22.0856 26.8024 21.636 26.3087C21.212 25.8444 21.4359 24.8111 21.324 24.0347C19.9933 14.8323 14.8727 8.80132 6.09057 5.85008C4.37689 5.28406 2.58381 4.99533 0.779072 4.99481C0.202773 4.99481 -0.0229751 4.83146 0.00455514 4.21479C0.0660406 3.08627 0.0660406 1.95525 0.00455514 0.826734C-0.0413285 0.0815827 0.259669 -0.0193618 0.896534 0.00266238C6.96236 0.222904 12.3693 2.24179 16.9889 6.16209C22.9794 11.2478 26.1271 17.7688 26.4372 25.648C26.4629 26.294 26.3179 26.5271 25.6609 26.4684C25.0827 26.417 24.4991 26.4574 23.7778 26.4574Z"> </path> <path d="M14.8265 26.441C14.0924 26.441 13.2371 26.6795 12.6626 26.3786C12.0092 26.0372 12.3781 25.0644 12.246 24.378C11.1154 18.5324 6.6849 14.5497 0.74755 14.1001C0.217135 14.0615 -0.0104482 13.9422 0.0134113 13.3659C0.0519536 12.1454 0.0482829 10.9213 0.0134113 9.69524C-0.00127145 9.14464 0.196946 9.03268 0.703502 9.04736C9.21217 9.27128 16.5994 16.2511 17.2804 24.7231C17.418 26.4446 17.418 26.4446 15.6579 26.4446H14.832L14.8265 26.441Z"> </path> <path d="M3.58928 26.4555C2.64447 26.4618 1.73584 26.0925 1.06329 25.4289C0.39073 24.7653 0.00933763 23.8617 0.0030097 22.9169C-0.00331824 21.9721 0.365937 21.0635 1.02954 20.3909C1.69315 19.7184 2.59675 19.337 3.54156 19.3306C4.48637 19.3243 5.39499 19.6936 6.06755 20.3572C6.7401 21.0208 7.1215 21.9244 7.12782 22.8692C7.13415 23.814 6.7649 24.7226 6.10129 25.3952C5.43768 26.0677 4.53409 26.4491 3.58928 26.4555Z"> </path> </svg> <span class="usa-sr-only">NCBI RSS feed</span> </a> </div> </div> <div data-testid="gridContainer" class="grid-container ncbi-footer__container"> <div class="grid-row ncbi-footer__main-content-container" data-testid="grid"> <div class="ncbi-footer__column"> <p class="ncbi-footer__circled-icons-heading"> Connect with NLM </p> <div class="ncbi-footer__circled-icons-list"> <a href=https://twitter.com/nlm_nih class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener"> <svg width="32" height="32" viewBox="0 0 40 40" fill="none" xmlns="http://www.w3.org/2000/svg" focusable="false" aria-hidden="true"> <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z"> </path> </svg> <span class="usa-sr-only">NLM on X (formerly known as Twitter)</span> </a> <a href=https://www.facebook.com/nationallibraryofmedicine class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener"> <svg width="13" height="24" viewBox="0 0 13 24" fill="none" xmlns="http://www.w3.org/2000/svg" focusable="false" aria-hidden="true"> <path d="M4.11371 23.1369C4.11371 23.082 4.11371 23.0294 4.11371 22.9745V12.9411H0.817305C0.6709 12.9411 0.670898 12.9411 0.670898 12.8016C0.670898 11.564 0.670898 10.3287 0.670898 9.09341C0.670898 8.97903 0.705213 8.95158 0.815017 8.95158C1.8673 8.95158 2.91959 8.95158 3.97417 8.95158H4.12057V8.83263C4.12057 7.8055 4.12057 6.7738 4.12057 5.74897C4.1264 4.92595 4.31387 4.11437 4.66959 3.37217C5.12916 2.38246 5.94651 1.60353 6.95717 1.1921C7.64827 0.905008 8.3913 0.764035 9.13953 0.778051C10.0019 0.791777 10.8644 0.830666 11.7268 0.860404C11.8869 0.860404 12.047 0.894717 12.2072 0.90158C12.2964 0.90158 12.3261 0.940469 12.3261 1.02968C12.3261 1.5421 12.3261 2.05452 12.3261 2.56465C12.3261 3.16857 12.3261 3.7725 12.3261 4.37642C12.3261 4.48165 12.2964 4.51367 12.1912 4.51138C11.5369 4.51138 10.8804 4.51138 10.2261 4.51138C9.92772 4.51814 9.63058 4.5526 9.33855 4.61433C9.08125 4.6617 8.84537 4.78881 8.66431 4.97766C8.48326 5.16652 8.3662 5.40755 8.32972 5.66661C8.28476 5.89271 8.26027 6.1224 8.25652 6.35289C8.25652 7.19014 8.25652 8.02969 8.25652 8.86923C8.25652 8.89439 8.25652 8.91955 8.25652 8.95615H12.0219C12.1797 8.95615 12.182 8.95616 12.1614 9.10714C12.0768 9.76596 11.9876 10.4248 11.9029 11.0813C11.8312 11.6319 11.7626 12.1824 11.697 12.733C11.6719 12.9434 11.6787 12.9434 11.4683 12.9434H8.26338V22.899C8.26338 22.979 8.26338 23.0591 8.26338 23.1392L4.11371 23.1369Z"> </path> </svg> <span class="usa-sr-only">NLM on Facebook</span> </a> <a href=https://www.youtube.com/user/NLMNIH class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener"> <svg width="21" height="15" viewBox="0 0 21 15" fill="none" xmlns="http://www.w3.org/2000/svg" focusable="false" aria-hidden="true"> <path d="M19.2561 1.47914C18.9016 1.15888 18.5699 0.957569 17.2271 0.834039C15.5503 0.678484 13.2787 0.655608 11.563 0.65332H9.43556C7.71987 0.65332 5.4483 0.678484 3.77151 0.834039C2.43098 0.957569 2.097 1.15888 1.74242 1.47914C0.813665 2.32097 0.619221 4.62685 0.598633 6.89384C0.598633 7.31781 0.598633 7.74101 0.598633 8.16345C0.626084 10.4121 0.827391 12.686 1.74242 13.521C2.097 13.8412 2.4287 14.0425 3.77151 14.1661C5.4483 14.3216 7.71987 14.3445 9.43556 14.3468H11.563C13.2787 14.3468 15.5503 14.3216 17.2271 14.1661C18.5676 14.0425 18.9016 13.8412 19.2561 13.521C20.1712 12.6929 20.3725 10.451 20.3999 8.22064C20.3999 7.74025 20.3999 7.25986 20.3999 6.77946C20.3725 4.54907 20.1689 2.30724 19.2561 1.47914ZM8.55942 10.5311V4.65201L13.5601 7.50005L8.55942 10.5311Z" fill="white" /> </svg> <span class="usa-sr-only">NLM on YouTube</span> </a> </div> </div> <address class="ncbi-footer__address ncbi-footer__column"> <p> <a class="usa-link usa-link--external" href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/%4038.9959508, -77.101021,17z/data%3D!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb%3A0x19156f88b27635b8!8m2!3d38.9959508! 4d-77.0988323" rel="noopener noreferrer" target="_blank">National Library of Medicine <br/> 8600 Rockville Pike<br/> Bethesda, MD 20894</a> </p> </address> <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column"> <li class="ncbi-footer__vertical-list-item"> <a href="https://www.nlm.nih.gov/web_policies.html" class="usa-link usa-link--alt ncbi-footer__link" > Web Policies </a> </li> <li class="ncbi-footer__vertical-list-item"> <a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office" class="usa-link usa-link--alt ncbi-footer__link" > FOIA </a> </li> <li class="ncbi-footer__vertical-list-item"> <a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' > HHS Vulnerability Disclosure </a> </li> </ul> <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column"> <li class="ncbi-footer__vertical-list-item"> <a href="https://support.nlm.nih.gov/" class="usa-link usa-link--alt ncbi-footer__link" > Help </a> </li> <li class="ncbi-footer__vertical-list-item"> <a href="https://www.nlm.nih.gov/accessibility.html" class="usa-link usa-link--alt ncbi-footer__link" > Accessibility </a> </li> <li class="ncbi-footer__vertical-list-item"> <a href="https://www.nlm.nih.gov/careers/careers.html" class="usa-link usa-link--alt ncbi-footer__link" > Careers </a> </li> </ul> </div> <div class="grid-row grid-col-12" data-testid="grid"> <ul class="ncbi-footer__bottom-links-list"> <li class="ncbi-footer__bottom-list-item"> <a href="https://www.nlm.nih.gov/" class="usa-link usa-link--alt ncbi-footer__link" > NLM </a> </li> <li class="ncbi-footer__bottom-list-item"> <a href="https://www.nih.gov/" class="usa-link usa-link--alt ncbi-footer__link" > NIH </a> </li> <li class="ncbi-footer__bottom-list-item"> <a href="https://www.hhs.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' > HHS </a> </li> <li class="ncbi-footer__bottom-list-item"> <a href="https://www.usa.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' > USA.gov </a> </li> </ul> </div> </div> </footer> <script type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/pinger/pinger.js"> </script> <button class="back-to-top" data-ga-category="pagination" data-ga-action="back_to_top"> <label>Back to Top</label> <svg class="usa-icon order-0" aria-hidden="true" focusable="false" role="img"> <use xlink:href="/static/img/sprite.svg#arrow_upward"></use> </svg> </button> <script type="application/javascript"> window.ncbi = window.ncbi || {}; window.ncbi.pmc = window.ncbi.pmc || {}; window.ncbi.pmc.options = { logLevel: 'INFO', staticEndpoint: '/static/', citeCookieName: 'pmc-cf', }; </script> <script type="module" crossorigin="" src="/static/assets/base-6f05ef93.js"></script> <script type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/jquery/jquery-3.6.0.min.js"> </script> <script type="text/javascript"> jQuery.getScript("https://cdn.ncbi.nlm.nih.gov/core/alerts/alerts.js", function () { galert(['div.nav_and_browser', 'div.header', '#universal_header', '.usa-banner', 'body > *:nth-child(1)']) }); </script> <script type="text/javascript">var exports = {};</script> <script src="/static/CACHE/js/output.13b077bc3ffd.js"></script> <script type="module" crossorigin="" src="/static/assets/article-7a2c2b27.js"></script> </body> </html>

CINXE.COM

Mifepristone (RU-486) treatment for depression and psychosis: a review of the therapeutic implications - PMC